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RÉSUMÉ 
L'infection virale et la transfonnation néoplasique engendrent du stress dans le 
réticulum endoplasmique (RE). En conséquence, une grande proportion de cellules qui 
devraient être reconnues par le système immunitaire, sont des cellules stressées. Lors d'un 
stress du RE, les cellules déclenchent une réponse envers les protéines mal repliées (UPR). 
L'UPR régule les deux processus clés qui contrôlent la présentation antigénique par les 
molécules du complexe majeur d'histocompatibilité de classe 1 (CMH 1) : la synthèse et la 
dégradation des protéines. Nous avons voulu détenniner si l'UPR affecte la présentation 
antigénique et comment. Tout d'abord, l'impact de l'UPR sur l'expression globale du CMH 
1 ainsi que sur la présentation du peptide SIINFEKL dérivant de la protéine ovalbumine a 
été évalué. Des cellules EL4 transfectées de façon stable avec des vecteurs codant pour des 
variantes de la protéine HEL-SIINFEKL ont été stressées à l'aide d'agents phannacologiques 
ou encore soumis à une carence en glucose. Nos résultats indiquent que l'UPR diminue 
l'expression du CMH 1 à la surface des cellules, mais n'a pas d'effet au niveau de l'ARN 
messager. Conséquemment, la présentation de SIINFEKL par les molécules H2Kb était 
diminuée dans les cellules stressées, autant de façon chimique que physiologique. De plus, les 
cellules stressées présentaient préférentiellement des complexes CMH I-peptide provenant 
de la variante protéique qui se localise dans le RE par rapport à ceux dérivant de la protéine 
cytosolique. Par ailleurs, suite à une élution des peptides avec de l'acide, la génération de 
peptides provenant de la protéine localisée dans le RE était moins affectée que dans le cas de 
la protéine cytosoliqué. Nos résultats démontrent que le stress du RE altère la présentation 
de complexes CMH I-peptide et qu'il régule de façon différentielle l'expression de peptides 
dérivant du RE ou du cytosol. Ainsi, notre recherche montre que le stress du RE, qui est une 
caractéristique des cellules infectées ou transfonnées, peut affecter les signaux nécessaires 
pour la reconnaissance par le système immunitaire. 
Mots clés: CMH de classe l, présentation antigénique, antigène/peptide, stress du RE, réponse 
envers les protéines mal repliées 
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SUMMARY 
Viral infection and neoplastic transformation trigger endoplasmic reticulum (ER) 
stress. Thus, a large proportion of the cells that must be recognized by the immune system are 
stressed cells. Cells respond to ER stress by launching the unfolded prote in response (UPR). 
The UPR regulates the two key processes that control major histocompatibility complex 
class l (MHC I)-peptide presentation: protein translation and degradation. We therefore 
asked whether and how the UPR impinges on MHC I-peptide presentation. We evaluated the 
impact of the UPR on global MHC l expression and on presentation ofthe Ovalbumin-derived 
SIINFEKL peptide. EL4 cells stably transfected with vectors coding HEL-SHNFEKL protein 
variants were stressed with pharmacological agents or exposed to glucose deprivation. UPR 
decreased surface expression ofMHC l at the protein but not the mRNA level. Consequently, 
presentation ofSIINFEKL by H2-Kb molecules was reduced in chemically or physiologically 
stressed cells. Notably, stressed cells preferentially presented MHC I-peptides derived from 
an ER-retained as opposed to a cytosol-Iocalized protein variant. Furthermore, generation of 
new H2Kb-SIINFEKL complexes after acid strip was less affected for ER- than for cytosol-
derived SIINFEKL. Our results show that ER stress impairs MHC I-peptide presentation, 
and that it differentially regulates expression of ER- vs. cytosol-derived peptides. This work 
indicates how ER stress, a typical feature of infected and malignant cells, can impinge on 
cues for adaptive immune recognition. 
Keywords: MHC c1ass I, antigen presentation, peptide/antigen, ER stress, unfolded protein 
response 
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1. INTRODUCTION 
1.1. General introduction 
A fundamental feature of infected and neoplastic cells is that they are stressed cells 
(Gleimer & Parham, 2003; Shin et al., 2003; Marciniak & Ron, 2006). Stressed cells express 
specific antigens that are recognized by T lymphocytes leading to eventual eIimination of 
tumor or infected cells (van der Bruggen & Van den Eynde, 2006; Hammer et al., 2007). 
The recognition of these antigens depends on the ability of cells to display their intracellular 
contents in the form of peptides bound to the major histocompatibility complex c1ass 1 
(MHC 1) molecules on the surface (Gleimer & Parham, 2003; Shin et al., 2003; Marciniak & 
Ron, 2006). Generating this complex repertoire of peptides and loading them on the MHC 
1 molecules for export to the cell surface, is accompli shed by the antigen processing and 
presentation pathway. 
Peptides suitable for loading the MHC 1 molecules, as well as peptide-receptive MHC 
1 molecules are generated in the endoplasmic reticulum (ER) (Hammer & Shastri, 2007). The 
ER stands at the crossroad of another fundamental process: maturation and folding of proteins 
destined to the secretory pathway. Eventually, the folding of proteins can be perturbed by 
viral infection and neoplastic transformation, which trigger ER stress (Marciniak & Ron, 
2006). Stressed cells respond by launching the unfolded protein response (UPR), an adaptive 
response that allows survival to limited stress but leads to apoptosis in the presence of 
overwhelming stress (Rutkowski et al., 2006; Szegezdi et al., 2006). In the following section 
1 will review these fundamental processes that constitute the basis of my research work. 
1.2. MHC I-antigen processing and presentation pathway 
The end result ofthe antigen processing pathway is the display of peptide-bound MHC 
1 molecules. These complexes are expressed on the cell surface, where they can be recognized 
by T cell antigen receptors (TCRs) of CD8+ T cells (Gleimer & Parham, 2003; Shin et al., 
2003; Marciniak & Ron, 2006). These peptides derive from the degradation ofvirtually aIl 
proteins inside the cell (Shastri et al., 2002) and represent proteins that are being translated 
at any given time (Jensen, 2007). In a stepwise manner, the antigen processing pathway 
generates and protects the proteolytic intermediates until they yield the final peptides that can 
fit the MHC 1 in the ER. This leads to MHC I-peptide complexes that are ready to be exported 
and presented. In the following section, we will see how this highly specialized pathway, 
operating with essentially conserved components, is nevertheless capable of generating 
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highly diverse sets of peptides that satisfy a large number of different MHC 1 molecules. 
1.2.1. Bringing the inside out: the immunopeptidome 
The repertoire of peptides presented by MHC 1 molecules, estimated to be composed 
of hundreds of thousands, is known as the MHC 1 immunopeptidome (Shastri et al., 2002; 
Shastri et al., 2005). Under steady-state conditions (in the absence of infection), cell surface 
MHC 1 molecules are associated solely with self-peptides. These peptides, colIectively 
referred to as the self-MHC 1 immunopeptidome (Istrail et al., 2004), play vital roles. They 
shape the repertoire of developing thymocytes (Huseby et al., 2003; Starr et al., 2003; Baldwin 
& Hogquist, 2007), transmit survival signaIs to mature CD8+ T celIs (Marrack & Kappler, 
2004) and influence mating preferences and other behaviors in mice (Slev et al., 2006). 
Thus, the self-MHC 1 immunopeptidome links the intracelIular milieu with the surrounding 
environment of almost aIl celI types (Shastri et al., 2002). 
The self-MHC 1 immunopeptidome also helps amplify responses against intracelIular 
pathogens (Anikeeva et al., 2006) and allows immunosurveillance of neoplastic celIs (Dunn 
et al., 2004; Zitvogel et al., 2006). It reflects the state of the celI since mutated genes, genes 
involved in differentiation or genes overexpressed in tumors modify and shape the self-MHC 
1 immunopeptidome (van der Bruggen & Van den Eynde, 2006). Moreover, viral proteins 
constitute a source of peptides that also molds the MHC I-peptide repertoire (YewdelI, 2007). 
Altogether, these modifications render the otherwise invisible internaI proteome available for 
surveillance by cytotoxic CD8+ T cells, which have the ability to detect and eliminate cells 
expressing viral proteins or tumor antigens (Shastri et al., 2002; Jensen, 2007). 
The immunopeptidome or MHC I-peptide repertoire is also involved III 
immunopathology since it can be targeted by autoreactive T cells that initiate autoimmune 
diseases and alloreactive T cells that cause graft rejection and graft-versus-host disease 
(Perreault et al., 1990; Liblau et al., 2002). The aforementioned roles of the immunopeptidome 
highlight its immunotherapeutic potential. In line with this, peptides overexpressed and/or 
specific to neoplastic cells can be used as targets in cancer immunotherapy (Singh-Jasuja 
et al., 2004; van der Bruggen & Van den Eynde, 2006; Purcell et al., 2007; Fortier et al., 
2008). 
The MHC 1 immunopeptidome is the result oftwo merging cellular pathways (Figure 
1). One pathway generates the peptides suitable for loading the MHC 1 molecules, whereas 
the second pathway produces peptide receptive MHC 1 molecules in the ER (Hammer et al., 
2007). 
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Figure 1. MUC l-antigen presentation pathway. Cytoplasmic proteins are degraded by the 
proteasome and other proteases. Resultant short peptides are transferred to the lumen of the 
ER by TAP in an ATP-dependent manner. Long peptides are trimmed by ER aminopeptidases 
such as ERAP 1. Peptides bound to MHC 1 molecules are exported via the secretory pathway 
and presented at the cell surface for surveillance by CD8+ T cells. Adapted from (Hanada & 
Yang, 2005). 
1.2.2. Peptide processing in the cytoplasm 
Generation of peptides suitable for loading MHC 1 molecules starts in the cytoplasm. 
This is the major site of protein degradation, because even ER pro teins are retrieved into 
the cytosol for turnover (Shastri et al., 2005). Thus, this compartment is the logical site for 
beginning the peptide-processing pathway (the pathway by which peptide substrates for MHC 
1 binding are made). Short peptides ofvariable lengths (2-25 amino acids) are generated from 
degradation of endogenous proteins in the cytoplasm through the action of the proteasome 
and other proteases (Stoltze et al., 2000a; Stoltze et al., 2000b; Jensen, 2007). Treatment of 
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cells with proteasome inhibitors has revealed that most but not all MHC I-peptide complexes 
require the prote as orne for their generation (Luckey et al., 1998). So, the majority of peptides 
are produced by the multicatalytic proteasome. 
Besides being the site where antigenic peptides are bom, the cytoplasm constitutes 
the site where most peptides are rapidly destroyed (Reits et al., 2003; Jensen, 2007). This 
rapid degradation by cytoplasmic peptidases limits the availability of peptides and accounts 
for the inefficiency of the peptide presentation pathway (Shastri et al., 2005). More than 
99% of peptides are degraded by cytosolic peptidases before they reach the ER (Yewdell et 
al., 2003). Cytosolic chaperones, su ch as Hsp70 (Heat shock prote in 70) and Hsp90 (Heat 
shock prote in 90), are thought to prote ct peptides from exhaustive degradation (Kunisawa & 
Shastri, 2003). 
Proteasomes are thought to generate the final carboxyl-terminal residues of MHC-
binding peptides (Cas cio et al., 2001), but additional trimming at the ami no terminus is 
required for most peptide epitopes (Jensen, 2007). Various cytosolic aminopeptidases are 
responsib1e for c1eaving the amino terminus (Rammensee, 2006). Of particu1ar interest is the 
cytoplasmic tripeptidyl peptidase II (TPPII), invo1ved in trimming of proteasoma1 products 
over 15 amine acids in length (York et al., 2006). TPPII has also been shown to participate 
in proteasome independent pathway for epitope generation (Guil et al., 2006). However, a 
delicate balance must be maintained because excess trimming by cytosolic peptidases can 
also destroy MHC 1 peptides. 
At this point, these peptides (usually less than 12 amino acids) constitute precursors 
of the MHC I-peptide repertoire and are ready to be translocated into the ER. However, as 
we will see later, these precursors need further trimming in the ER in order to be suitable for 
loading MHC 1 molecules. 
1.2.3. Generation of peptide-receptive MHC 1 molecules 
As mentioned above, production of the MHC 1 immunopeptidpme requires a 
concomitant pathway that generates peptide receptive MHC 1 molecules in the ER. The MHC 
1 molecules are heterodimers of a polymorphic heavy chain (a chain) and ~2-microglobulin 
(~2-m) (Zhang & Williams, 2006). Similar to what occurs with the peptide precursors, both 
polypeptides are cotranslationally translocated into the ER (Hammer et al., 2007). 
Once in the ER, early folding and oxidation of the MHC 1 heavy chain and ~2-m are 
mediated by the chaperone ca1nexin (Jensen, 2007). These events are followed by release from 
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calnexin and assembly with the MHC 1 peptide-loading complex (PLC) (Jensen, 2007) (Figure 
2). The PLC comprises many components, inc1uding the soluble chaperone calreticulin (CRT), 
the transmembrane protein tapasin, the oxidoreductase ERp57, protein disulfide isomerase 
(POl) and the heterodimeric transporter associated with antigen processing (TAP) (Zhang 
& Williams, 2006; Jensen, 2007). The luminal domain of TAP acts as a binding platform 
for calreticulin and ERp57, supporting the correct folding of MHC 1 in the PLC (Cresswell, 
2005; Cresswell et al., 2005). This multisubunit strucmre keeps the MHC 1 molecules in a 
peptide-receptive state (Hammer & Shastri, 2007). Nevertheless, MHC 1 heterodimers need 
to be stabilized by binding to a high-affinity peptide. 
ERAAP 
-
Il 
Cel surface 
+ 
.// 
.~ •• '~fl'''Htt.tl.H~~.41'IH' 'H ••• I.~~141~~HH.1 
TAP .... 
__ ~ ~ Peptide pool 
Cytoplasm 
Figure 2. Schematic depiction of the MHe 1 PLC. The MHC 1 molecule folds with the 
assistance of the chaperones calnexin (not shown) and calreticulin (CRT). The multisubunit 
PLC is centered on TAP. The adaptor molecule tapasin interacts with TAP and the MHC 
1 molecule and forms a covalent disulphide bond (S-S) with ERpS7 with the help of POl. 
ERAAP trims N-terminal extensions ofantigenic precursors, resulting in the generation of the 
final MHC I-peptide complex that is transported to the cell surface. Adapted from (Hammer 
et al., 2007). 
1.2.4. Peptide processing in the ER 
Besides retaining empty MHC 1 molecules, TAP is responsible for the active transport 
of peptide precursors into the lumen of the ER (Neefjes et al., 1993). This provides the 
empty MHC 1 heterodimers with easier access to the incoming peptide supply (Cresswell 
et al., 2005). TAP is a heterodimer composed of the TAPI and TAP2 molecules and shows 
substrate specificity when selecting peptides for translocation (Seliger et al., 1997; Gramme 
& Neefjes, 2002). lt is important to mention that the import of sorne peptides appears to be 
TAP-independent (Lautscham et al., 2003). 
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Peptide precursors are translocated in a naked fonn into the ER and can then follow 
one or more different fates. They can bind MHC 1 molecules, bind ER chaperones, be trimmed 
by ER aminopeptidases, be degraded or be retrotranslocated back into the cytosol (Elliott & 
Neefjes, 2006). Together, these processes keep the concentration of peptides low in the ER 
su ch that only the most recent peptides are available for MHC 1 binding and do not have to 
compete with those that arrived earlier (Yewdell et al., 2003). 
MHC 1 molecules are promiscuous, and they bind many different peptides with certain 
amino acid preferences at key positions (anchor residues) which constitute binding motifs 
(Rammensee et al., 1999). High-quality peptides that confer stability to the MHC 1 molecules 
share two important properties: the precise length and amino acid sequence required for 
a given MHC c1ass I-binding motif (Hammer et al., 2007). Peptides entering the ER via 
TAP bind to newly synthesized MHC 1 molecules immediately, as long as the C-tenninus is 
correct and the appropriate motif is present (Rammensee, 2006). At this stage, the length is 
not yet crucial (Rammensee, 2006). Peptides with a proper MHC 1 motif, but still too long on 
their N-tenninus, do bind to MHC 1 molecules. Initial peptide binding is followed by peptide 
exchange and editing in the ER (Elliott & Williams, 2005) (Figure 3) . 
. ~ ...... -Proteasome & peptidase6 
MHC~SI 1 
heavy chain CalnexJn 
• • Calretlculln • 
lf,M POl 
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Peptlde·loadlng complex 
. -Endogenous Peptlde 
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Figure 3. The MUe 1 processing pathway. MHC I heavy chains initially assemble with 
~2-m , followed by recruitment into the PLC in the ER. Endogenous peptides, generated in 
the cytoplasm through the action ofproteasomes and other peptidases are transported into the 
ER via TAP. ERAAP mediates final N-tenninal trimming before or after binding to MHC I 
molecules. PLC promo tes peptides loading and exchange, providing quality control for the 
preferential export of kinetically stable MHC I-peptide complexes. Adapted from (Jensen, 
2007). 
Generation of correct MHC 1 binding peptides sometimes requires trimming by ER 
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aminopeptidases. The key enzyme responsible for generation of quality peptides and final 
amino-terminal trimming in the MHC c1ass I pathway is the ubiquitously expressed ER 
amino peptidase associated with antigen processing, ERAAP in mice (ERAP1I2 in humans) 
(Serwold et a1., 2002). ERAAP recognizes the peptide carboxyl terminus and trims the amino 
terminus to generate peptides 8-10 residues in length (Chang et a1., 2005). This enzyme is 
induced by interferon gamma (IFN -y), a proinflammatory cytokine that enhances antigen 
presentation (Saric et a1., 2002; Serwold et a1., 2002). Importantly, ERAAP serves a unique 
function in modifying the MHC I-peptide repertoire and influencing CD8+ T cell responses; 
ERAAP deficiency leaves sorne peptides unaffected, whereas others are either absent or 
dramatically upregulated (Hammer et a1., 2006). 
Peptide precursors can also bind ER chaperones (Spee et a1., 1999). PDI appears to 
be the most efficient peptide-binding ER chaperone, as it binds to peptides of different length 
and sequence (Park et a1., 2006). Importantly, binding of peptides to PDI protects them from 
degradation (Elliott & Neefjes, 2006). 
Finally, peptides not containing a fitting motif and thus not bound to MHC 1 molecules, 
are trimmed and destroyed by ERAAP (Kanaseki et a1., 2006), or retrotranslocated back into 
the cytosol for ER-associated degradation (ERAD) (Elliott & Neefjes, 2006). In this way, 
they no longer compete for space in the local compartment. 
1.2.5. Peptide loading and presentation 
The PLC represents the precise point of intersection between the pathways of peptide 
processing and peptide presentation. The PLC orchestrates the final assembly of MHC 1 
molecules with peptides (now 8-11 amino acids), delivered into the ER by TAP, for generation 
of stable MHC c1ass I-peptide complexes (Jensen, 2007). Its chief function is to provide 
'quality control' by selectively retaining MHC 1 molecules loaded with suboptimal peptides 
for replacement by higher-affinity quality peptides (Hammer et a1., 2007). 
When any ofthe PLC constituents are missing or are inhibited by viruses, intracellular 
MHC 1 molecules can suffer unfolding, degradation and indiscriminate peptide loading, aU of 
which can compromise the stability, expression and function ofMHC I-peptide complexes at 
the cell surface (Hammer et a1., 2007). 
Finally, after successful peptide loading and customization, MHC c1ass 1 -peptide 
complexes are released from the PLC and are transported through the Golgi cistemae and 
the constitutive secretory pathway to the cell surface (Jensen, 2007). Indeed, only 1-2 out 
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of every 10,000 peptides generated by the proteasome bind to MHC 1 molecules (Yewdell et 
aL, 2003). 
Different MHC alleles have different motifs and bind different set of peptides. The 
number of class 1 MHC molecules per cell is estimated at 50,000-100,000 (Gakamsky et al., 
2000). Since as many as 2x106 peptides are estimated to be generated every second, only a 
small minority of peptide epitopes can be presented on a MHC 1 at any time (Princiotta et al., 
2003). Most peptides are represented at fewer than ten copies per celL However, it has been 
estimated that only three copies of the antigenic peptide are sufficient for target celllysis by 
cytotoxic T ceUs (CTLs) (Purbhoo et al., 2004). 
1.3. The origin of peptides for display by MHC 1 molecules 
The complexity ofthe MHC I-immunopepidome reflects the equally complex milieu 
of intracellular proteins (Shastri et al., 2005). It is widely known that peptides displayed by 
MHC 1 molecules derive from degradation of proteins acquired from an exogenous source 
or from proteins endogenously synthesized, in processes referred to as cross-presentation or 
direct presentation, respectively (Shastri et al., 2005). When and how intraceUular proteins 
are chosen for entry into the antigen processing pathway? This is an interesting yet not 
completely solved question. What is now clear, however, is that the MHC I-peptide repertoire 
is not a random sample of the proteome: many abundant proteins do not generate MHC 
I-associated peptides white sorne low abundant proteins have a major contribution to the 
immunopeptidome (Caron et al., 2005; Milner et al., 2006). In the foUowing section, 1 will 
give sorne examples of generation of peptides from exogenous proteins and de scribe more in 
detail the mechanisms by which endogenous proteins can give rise to peptides. 
1.3.1. Exogenous proteins as source of peptides 
Uptake of exogenous antigens occurs routinely in antigen-presenting ce Us (APCs) 
such as macrophages and dendritic cells (DCs), which represent the sentinels for initiating 
naïve CD8+ T-cell responses (Mellman & Steinman, 2001). The transferred antigens can take 
many different forms, ranging from cell debris from apoptotic or necrotic ceUs to proteins or 
chaperone-associated peptides (Trombetta & Mellman, 2005). For instance, DCs can ingest 
infected ceUs or cancer ceUs and derivè antigens from these sources in a mechanism known as 
cross-presentation (J ensen, 2007). AIso, exogenous protein sources are clearly important in the 
presentation of peptides derived from intracellular pathogens such as Listeria monocytogenes 
(Pamer et al., 1997). 
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There are many pathways for cross-presentation, including TAP-dependent and TAP-
independent mechanisms, ev en though the former seem to dominate. Exogenous antigens can 
be transferred from the endosome to the cytosol, where they are digested by proteasomes and 
loaded onto MHC 1 molecules in a TAP-dependent manner (Trombetta & Mellman, 2005). 
It remains unclear, however, what the mechanisms are by which they traverse the enosomal 
membrane and reach the cytoplasm. Suggested mechanisms involve transient physical rupture 
of the endosomal membrane or the action of a specific channel or translocator (Trombetta & 
Mellman, 2005). Altematively, antigens might make use of an established retro grade pathway 
leading from endosomes to the ER via the Golgi. Form the ER, they may reach the cytosol 
using the translocation channel involved in retro translocation during prote in degradation 
(Trombetta & Mellman, 2005). As in the MHC 1 processing pathway, there is a balance 
between peptide generation and destruction by proteolytic enzymes in cross-presentation. 
Mechanisms that reduce the activity of endosomal hydrolases in DCs have recently been 
shown to enhance the efficiency of cross-presentation (Jensen, 2007). 
To some extent, exogenous antigens can also be presented on MHC 1 molecules in 
a TAP-independent manner, indicating that they do not require transport to the cytosol and 
can thus be loaded in the endocytic pathway (Trombetta & Mellman, 2005). This pathway 
may involve peptide exchange in recycling endosomes or on the cell surface, and a recent 
study has demonstrated that the lysosomal protease cathepsin S is important in generating 
peptides presented through this pathway (Jensen, 2007). Recently, it has been demonstrated 
that peptides can be transferred from virally-infected cells to professional APCs through gap 
junctions (Neijssen et al., 2005). 
1.3.2. Endogenous proteins as source of peptides 
Most endogenous proteins destined for presentation on MHC 1 molecules are fed to 
the proteasome to initiate fragmentation. However, the source of proteasomal substrate is 
quite varied. Peptide ligands for MHC 1 molecules can be derived from cryptic transcription 
products, defective ribosomal products (DRiPs), "stable" proteins or from retrotranslocation 
of proteins destined to the secretory pathway from the ER to the cytosol (Figure 4). 
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Figure 4. Possible sources ofproteins presented on MHC 1 molecules. MHC 1 ligands have 
been shown to derive from various sources, including (1) cytosolic proteins, (2) alternative 
translation products and DRiPs, (3) proteins retrotranslocated to the cytosol from the ER, and 
(4) internalized proteins transferred to the cytosol. Adapted from (Trombetta & Mellman, 
2005). 
1.3.2.1. Peptides derived trom stable proteins 
MHC I-peptide ligands can be obtained from "stable" proteins, as evidenced by 
presentation of several species of posttranslationally modified peptides: N-glycosylated 
peptides, de-aminated peptides (Mosse et al., 1998), phosphopeptides (Zarling et al., 2006) 
or peptides with modified cysteine residues (Chen et al., 1999). 
1.3.2.2. Rapidly versus slowly degraded polypeptides 
As mentioned above, most of the peptides that enter the MHC 1 presentation pathway 
are generated by proteasome-mediated cleavage of polypeptides (Schubert et al., 2000). Note 
that the process of fragmenting a protein for generating an antigenic peptide is mutually 
exclusive from the process ofusing the same protein molecule to fold into a biologically active 
form. In principle, proteins can be sampled either at the beginning, the end, or anywhere in 
the middle oftheir lifespan. Proteins exhibit a wide range of degradation rates: from minutes 
to weeks, with an overall half-life of 1-2 days (Yewdell & Nicchitta, 2006). Polypeptides 
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have been segregated into two general pools: (1) those degraded with an average half-life 
of -10 minutes, named rapidly degraded polypeptides (RDPs), and (2) those degraded with 
an average half-life from hours to weeks (in average -2000 minutes), referred to as slowly 
degraded polypeptides (SDPs) (Yewdell & Nicchitta, 2006) (Figure 5). 
DAiPs 
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Figure 5. IntracelluIar polypeptide degradation pools. Polypeptides segregate into two 
general pools: those degraded with an average half-life of ~ 10 min (RDP) and those degraded 
with an average half-life of ~2000 min (SDP). DRiPs belong to the RDP or to the SDP pool , 
although it seems likely lhat most nalurally generated DRiPs belong to the RDP pool. MHC 
I-peptide ligands (CI-PLs) seem to be predominantly derived from subslrates in the RDP 
pool. These substrates include DRiPs and c1eaved leader sequences. Adapted from (Yewdell 
& Nicchitta, 2006). 
A significant proportion of peptides appears to result from the degradation of newly 
synthesized, but rapidly degraded polypeptides as opposed to slowly degraded polypeptides 
(Reits et al., 2000; Schubert et al., 2000). These RDPs are presumably weil represented 
by either misfolded or erroneous proteins, which have been called DRiPs (Yewdell et 
al., 1996; Princiotta et al., 2003; van der Bruggen & Van den Eynde, 2006). Remarkably, 
RDPs could constitute 1 % or Jess of newly synthesized proteins, yet still provide ail of the 
peptides presented by MHC 1 molecules (Yewdell & Nicchitta, 2006). Strong evidence has 
been published supporting the idea that translation and protein folding must be error prone 
(Jensen, 2007) and that newly generated polypeptides, including DRiPs, represent the main 
source of antigens entering the MHC 1 loading pathway (Yewdell, 2005; Yewdell & Nicchitta, 
2006). Thus, it has been suggested that, MHC 1 molecules preferentially sample what is being 
translated as opposed to what has been translated (Qian et al., 2006a; Qian et al., 2006b). 
Accordingly, the MHC 1 peptide repertoire has been shown to be biased toward peptides 
derived from highly abundant transcripts (Fortier et al., 2008). To note, long-lived intact 
proteins can also contribute to the peptide pool although possibly in a lesser extent (Yewdell 
& Nicchitta, 2006). 
1.3.2.3.Driving force for peptide generation: the DRiPs hypothesis 
Most proteins, including those that contain MHC l-restricted epitopes, are tumed 
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over very slowly with half-lives of many hours if not days (Eisenlohr et al., 2007). Yewdell 
et al. pointed out that this rate is inconsistent with in vitro assays showing that cells become 
recognizable by CD8+ T cells soon after they are infected and that peptide production must 
commence very shortly after protein synthesis (Yewdell et al., 1996). 
Consequently, Yewdell et al. proposed that immediate peptide supply is driven not by 
senescence of mature proteins but by newly synthesized proteins that are defective, termed 
DRiPs (Yewdell et al., 1996). These DRiPs, comprising polypeptides that fail to achieve 
its native structure, owing to imperfections in transcription, splicing, translation, post-
translational modifications or protein folding, are ftagged by the quality-control machinery 
and rapidly degraded (Yewdell et al., 1996) (Figure 6). 
Figure 6. The ORiPs hypothesis.Accurnulated errors during protein production (transcription, 
translation and fol ding) can lead to defective proteins that are instantly recognized by the 
quality-control rnachinery and targeted for rapid degradation, with sorne products ultirnately 
becorning MHC I-bound epitopes. Misfolded proteins are subdivided into severely rnisfolded 
proteins that are degraded by the 20S proteasorne and rnoderately rnisfolded proteins that are 
degraded by the 26 proteasorne. Adapted frorn (Eisenlohr et al., 2007). 
The DRiPs hypothesis was initially supported by sorne indirect evidence. First, 
early studies showed that mutant proteins that cause disease, as weil as misfolded proteins 
induced in the presence of certain compounds, are immediately degraded after their synthesis 
(Knowles et al., 1975; Rieder et al., 1975). Second, a substantial fraction ofnewly synthesized 
proteins is rapidly turned over. This fraction has been estimated to correspond to 40% and 
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30% per hour (Wheatley et al., 1980; Yewdell et al., 1996; Schubert et al., 2000). Third, 
increasing the degradation rate of an antigen results in a substantially higher level of epitope 
production (Townsend et al., 1988). The DRiPs hypothesis was subsequently supported by 
experimental results showing that peptide production ceased 30 minutes after inhibition of 
protein synthesis, suggesting that mature prote in turnover is too slow to make a meaningful 
contribution to the peptide pool (Reits et al., 2000; Yewdell, 2005). 
Nevertheless, sorne aspects of the DRiPs hypothesis have been questioned (Eisenlohr 
et al., 2007). First, a DRiP has not yet been identified nor produced (Yewdell, 2005). Second, 
a window of30 minutes for peptide production, implies a very short half-life of 15 minutes or 
less for the substrates from which the peptides are derived (Princiotta et al., 2003) and a quickly 
disposaI of defective proteins. This seems not to be in line with current concepts of prote in 
production and quality control arguing against the DRiPs model (Eisenlohr et al., 2007). On one 
side, there is an ever growing list of 'natively' or 'intrinsically' unfolded proteins that bypass 
the quality control machinery and are not degraded (Eisenlohr et al., 2007). On the other side, 
many misfolded proteins can be rescued by prolonged interaction with HSPs (Markossian & 
Kurganov, 2004; True, 2006). Concordantly, increased degradation is not always the fate of 
misfolded proteins. They can enter aggregates that resolve very slowly or not at all, becoming 
candidates for ubiquitin-mediated autophagy and not proteasomal degradation (Bukau et al., 
2006). The DRiPs model has also been called into question by recent evidence showing that 
newly synthesized polypeptides are mostly protected from prote as omal degradation during 
and immediately after translation and that preexisting proteins represent the main proteasome 
substrates (Vabulas & Hartl, 2005). 
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A recent alternative model, not exduding the DRiPs hypothesis, proposes that 
a subset of nascent polypeptides is stochastically delivered to the 20S proteasome owing 
to neglect by the folding machinery (Eisenlohr et al., 2007) (Figure 7). This subset would 
presumably correspond to 25% of all synthesized proteins (Qian et al., 2006a). For a given 
antigen, the basallevel of peptide presentation from immediately degraded substrate by the 
20S proteasome will be supplemented by the cohort of newly synthesized proteins that is 
successfully intercepted by the folding machinery (Eisenlohr et al., 2007). The more defective 
the prote in is, the sooner and more intense the presentation of the peptide will be, which is 
due to more rapid rejection by the quality control machinery. 
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Figure 7. An alternative to the DRiPs modeI. Most mRNAs are translated by ribosomes 
associated with HSPs such as RAC and NAC, resulting in partial compaction of the nascent 
polypeptide and its delivery to downstrearn chaperones. If the prote in carries an overt 
degradation signal (degron), then degradation starts immediately (b). If it carries a covert 
degron, then it is rapidly degraded after having achieved the mature state (f). Proteins are 
identified as defective at different steps towards maturation (a and c). A small fraction of 
mRNAs is translated by unengaged ribosomes and these unfolded protein species are degraded 
by the 20S proteasome (a). Adapted from (Eisenlohr et al., 2007). 
1.3.2.4. Cryptic translation as a source of naturally processed peptides 
ln addition to conventional translation products, cells can also generate peptide 
ligands for MHC 1 molecules from cryptic translation products. Cryptic translation refers to 
polypeptides that are synthesized by unconventional translational mechanisms. These include 
peptides encoded by open reading frames contained within 5' and 3' untranslated regions, 
alternative open-reading frames, introns, or intron-exon junctions (Bullock & Eisenlohr, 
1996; Mayrand et al., 1998; Shastri et al., 2002; Cardinaud et al., 2004). The list of MHC 
I-peptides derived from cryptic translation has been steadily growing (Ho & Green, 2006). 
Many examples of peptides ofviral origin or in tumor cells have been described (Ho & Green, 
2006). Cryptic translation also operates in nonnal professional as weIl as non-professional 
APCs (Schwab et al., 2003). Although cryptic peptides are expressed at low abundance within 
the MHC I-peptide pool, they have been shown to induce tolerance in transgenic mice that 
generate cryptic peptides, and elicit CD8+ T-cell responses in nonnal mice (Schwab et al., 
2003). Besides cryptic translation, translational errors, including ribosomal frameshifting, 
can have biological relevance in generating CD8+ T cell detenninants (Zook et al., 2006). 
1.3.2.5. Peptides derived from peptide splicing 
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It has been reported that MHC 1 ligands can contain sequences that are not contiguous 
in the original protein but are spliced together from neighboring peptides (Hanada et al., 2004; 
Vigneron et al., 2004; Hanada & Yang, 2005; Warren et al., 2006). They represent spliced 
peptides generated by the proteasome. This suggests that the number of MHC I-peptides 
could be potentially larger than anticipated. 
1.3.2.6. Peptides derived From proteins destined to the secretory pathway 
Secretory and membrane proteins are also a known source of MHC I-peptides. 
Nevertheless these proteins have to exit the ER because there are no proteasomes present in 
the ER lumen (Wojcik & DeMartino, 2003). Proteins destined to the secretory pathway can 
gain access to the cytosol after being retrotranslocated from the ER, in a process that typically 
results in ubiquitination and proteasomal degradation, defined as ER-associated degradation 
(ERAD, see below) (Tsai et al., 2002). Many peptides derived from transmembrane or 
secretory proteins correspond to sequences derived either from transmembrane regions or 
signal sequences (Shastri et al., 2005). 
1.4. Translation and Protein Folding 
Protein synthesis is energetically the most expensive process in the cell. It places 
heavy demands upon the cell in terms of requirements of both amino acids and metabolic 
energy (Proud, 2007). Not surprisingly, translation rates are tightly regulated to match 
the requirements of the cell/tissue with the supply of metabolic energy and amine acids. 
Regulating the overall rate of protein synthesis is important not only for modulating cell and 
tissue metabolisni and growth, but also for controlling gene expression (Proud, 2007). Cell 
proliferation also depends upon maintaining an adequate rate of prote in synthesis (Scheper 
et al., 2007). 
Protein synthesis is mediated by ribosomes. Ribosomes comprise two subunits: the 
'large' subunit (60S in mammals) and the 'small' subunit (40S in mammals) (Scheper et al., 
2007). The process of translation itself requires several other proteins, which are known as 
translation factors (Scheper et al., 2007). rnRNA translation is conventionally divided into 
three stages: initiation, elongation and termination. During initiation, the ribosome and the 
tRNA for the first amino acid residue (methionyl-tRNA) are positioned at the first codon 
(AUG) of the mRNA. During elongation, the polypeptide chain is assembled step-by-step as 
dictated by the ORF of the mRNA. When the ribosome encounters a stop codon, termination 
occurs, resulting in release of the completed polypeptide and the ribosomal subunits (Scheper 
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et al., 2007). 
Accuracy is essential at aIl these stages, particularly in locating the start codon. For 
most mRNAs, this involves a process whereby the 40S ribosomal subunit is recruited to the 
mRNA's 5' cap structure. Together with the methionyl-tRNA and certain translation initiation 
factors, the 40S subunit then scans along the 5' untranslated regions (5'UTR or 'leader') of 
the mRNA to find the start codon. In sorne cases, features within the 5' UTR allow the 40S 
subunit to enter downstream of the 5' cap, largely obviating the need for scanning. Such 
internaI ribosomal entry sites (IRES) were first found in certain viral RNAs, but also occur 
in a subset ofhuman cellular messengers (Jackson, 2005). Nevertheless, in eukaryotes, most 
mRNAs are translated in a cap-dependent manner. 
Both 5' and 3' UTRs can contain other elements that modulate the efficiency ofmRNA 
translation. Furthermore, sequences in the 3' UTR can affect translation through interaction of 
the poly-A-binding prote in with eukaryotic initiation factor (eIF) 4F (Mangus et al., 2003). 
It is worth to note that translation also occurs in mitochondria. N onetheless, the 
components of the mitochondrial protein synthesis machinery are quite distinct from their 
cytosolic counterparts, generally being more similar to those of bacteria (Scheper et al., 
2007). 
After synthesis, proteins must rapidly fold to perform their biological activities. 
Folding takes place in three main subcellular compartments: cytosol, ER and mitochondria. 
Each organelle is equipped with a specific set of chaperones and folding enzymes (Anelli 
& Sitia, 2008). Whereas it is generally accepted that the ER functions uniquely in the 
biogenesis of secretory and integral membrane proteins, it has been recently shown that the 
ER membrane also supplies a substantial portion ofnewly synthesized proteins to the cytosol 
(Stephens & Nicchitta, 2008). The following section, l will concentrate on the mechanism by 
which proteins destined to the secretory pathway are produced, since it is the most studied 
and best understood. 
1.4.1. rnRNA partitioning and translation in the ER 
mRNA partitioning between the cytosol and the ER compartments is an 
ubiquitous, highly conserved property of eukaryotic cells that serves to create a dramatic 
compartmentalization of protein synthesis: in general, mRNAs encoding cytosolic proteins 
undergo translation on free ribosomes, whereas mRNAs encoding secretory and integral 
membrane proteins are translated on ER-bound ribosomes (Nicchitta et al., 2005) (Figure 
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Figure 8. The SRP-ribosome cycle. Cytosolic ribosomes engaged in the translation of 
mRNAs encoding secretory or membrane proteins, are targeted through the SRP pathway to 
the ER membrane. At the ER, the signal sequence engages the protein-conducting channel 
and prote in translocation ensues. Termination of the protein synthesis leads to the release 
of ribosomal subunits from the ER membrane to the cytosol. L: large ribosomal subunit, S: 
small ribosomal subunit. Adapted from (Nicchitta et al., 2005). 
A considerable fraction of the proteome consists of molecules that are either secreted 
or inserted into membranes, to act as ligands and receptors, respectively (Anelli & Sitia, 2008). 
Proteins destined to the secretory pathway are directed to the ER through a predominantly 
hydrophobie signal sequence (Schroder & Kaufman, 2005). They are synthesized on ER-
bound ribosomes, and are cotranslationally translocated into the ER lumen where they 
attain their native conformation, before being transported to the Golgi and downstream 
compartments (Anelli & Sitia, 2008). 
In general, in the absence of an encoded signal sequence, rnRNAs undergo continued 
translation on cytosolic ribosomes (Nicchitta et al., 2005). In the case ofmRNAs containing 
a signal sequence, the mRNA-ribosome-nascent chain complex is relayed to the membrane 
by the signal recognition partic1e (SRP) early in translation (Nicchitta et al., 2005). The SRP 
elicits a suppression oftranslation and enables the trafficking of complexes to the ER (Meyer 
& Dobberstein, 1980). Then the protein traverses the ER membrane through an aqueous 
channel, named the Sec61 p complex (Schroder & Kaufman, 2005). Sequential interactions of 
the mRNA-ribosome-nascent chain complex with the SRP receptor and with Sec61p, results 
in the release of the SRP, the binding of the ribosome to Sec61 p, and a coupled process of 
protein synthesis and protein translocation (Stephens & Nicchitta, 2008). 
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The signal peptide is then cleaved off by signal peptidase (Schroder & Kaufman, 
2005). Indeed, the signal sequence influences the timing ofN-linked glycosylation and signal 
sequence cleavage (Rutkowski et al., 2003). AIso, inefficient cleavage can result in prolonged 
interaction of the protein with ER chaperones (Stevens & Argon, 1999). 
1.4.2. Protein folding in the ER 
Initial stages ofprotein folding, which consist of shie1ding and compacting hydrophobie 
domains, are carried out by chaperones of the HSP family (Frydman, 2001). Specialized 
HSPs, positioned at the exit channel of the ribosome, rapidly intercept nascent polypeptides. 
ln yeasts and higher eukaryotes, this function is carried out by two different complexes: 
the heterodimeric nascent polypeptide-associated complex (NAC) and the HSP70-associated 
ribosome-associated complex (RAC) (Wegrzyn & Deuerling, 2005; Wegrzyn et al., 2006). 
Partially compacted pro teins are then transferred to the chaperonins, which shepherd the 
substrate through the final stages of condensation (Eisenlohr et al., 2007). 
Many principles goveming protein folding in the cytoso1 apply to the ER. However, 
protein folding in the ER is more complex than protein folding in the cytosol because proteins 
are posttranslationally modified (Schroder & Kaufman, 2005). The ER is unique in sustaining 
a set of covalent modifications, which include removal of the signal sequence, disulfide bond 
formation, N-glycosylation and glycophosphatidylinositol (GPI) addition. To note, removal 
of signal sequence and N-glycosylation are unique to secretory proteins (Anelli & Sitia, 
2008). Different chaperones and folding assistants de termine different folding pathways, 
su ch as the calnexin/calreticulin (CNXlCRT) cycle or the Binding Prote in (BiP, also 
called GRP78) pathway. The choice of one or another is dictated by the localization of the 
N-glycans: the closer these are to the N-terminus, the higher the tendency to use CNXlCRT 
as a chaperone system (Molinari & Helenius, 2000). Very rarely glycoproteins are found to 
bind simultaneously BiP/GRP78 and CNXlCRT (Anelli & Sitia, 2008). AIso, certain proteins 
that are produced in large amounts are assisted by substrate- or tissue-specifie chaperones 
(Anelli & Sitia, 2008). 
1.4.2.1. N-glycosylation and the CNX/CRT cycle 
N-glycosylation involves binding ofa preformed oligosaccharide (Glc3Man9GlcNAc) 
to consensus Asn-X-Ser/Thr residues (Figure 9). The sugar moieties are then progressively 
trimmed by resident enzymes. Soon after synthesis, glucosidases 1 and II sequentially rem ove 
the three glucoses from the A branch of the oligosaccharide. UDP-glucose glycoprotein 
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glucosyltransferase (UGGT) adds back a glucose residue to N-glycans (Taylor et al., 2004). 
The produced monoglucosylated proteins (Glc 1 Man9GlcNAc2) can then interact with CNX 
or CRT, two ER chaperones with lectin activity (Williams, 2006). Besides retaining misfolded 
proteins and preventing their aggregation (see Protein quality control section), CNX and 
CRT promo te oxidative folding via interactions with ERp57. Then, by removing the terminal 
glucose, glucosidase II dissociates the substrate from CNX/CRT (Anelli & Sitia, 2008). If 
the prote in has attained its native structure, it can now proceed along the secretory pathway 
by bulky flow or by interaction with specific lectin transporters such as ERGIC-53 (ER-
Golgi intermediate compartment-53) or VIPL (Anelli & Sitia, 2008). However, if unfolding 
persists, the protein enters the CNXlCRT cycle again. On the other side, mannose trimming 
causes exit of terminally misfolded proteins from the cycle (Anelli & Sitia, 2008). The fate 
of misfolded proteins will be discussed in further sections. 
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Figure 9. The CNXlCRT cycle. After transfer of the preformed core oligosaccharide onto 
nascent proteins, glucosidase 1 and II sequentially remove two terminal glucoses. The 
resulting monoglucosylated protein interacts with CNX and CRT, which in association with 
ERp57 prevents aggregation and facilitates folding_ Removal of the glucose by glucosidase 
Il liberates the protein form CNX and CRT. If the protein has attaint its native structure, it 
follows the secretory pathway by bulky fiow or by interaction with transporters. If unfolding 
persists, UGGTI places a single glucose back onto the protein, causing its entrance into the 
CNX/CRT cycle. Mannose trimming causes exit ofmisfolded proteins that can be targeted to 
ERAD. Adapted from (Anelli & Sitia, 2008) 
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1.4.2.2. The BiPIGRP78 pathway 
The affinity of BiP/GRP78 for substrates depends on ATP. Thus, substrates can 
undergo cycles of BiP/GRP78 binding and release, depending on ATP hydrolysis (Anelli & 
Sitia, 2008). This process is regulated by hsp40-like co-chaperones containing a J domain 
(ERdj) (Shen et al., 2002). 
1.4.2.3. Oxidative fa/ding 
A hyper-oxidizing environment in the ER lumen may inhibit folding of proteins with 
multiple disulfides. Therefore, oxidative folding relies primarily on the PDI pathway. PDI or 
PDI-like proteins catalyze disulfide bond formation in the ER (Anelli & Sitia, 2008). After 
transferring a disulphide bond to nascent proteins, PDI is re-oxidized by members of the Ero 1 
flavoprotein family (Anelli & Sitia, 2008). 
1.5. Protein quality control in the secretory compartment 
As we have seen, the ER provides an environment that facilitates the folding 
and assembly of newly synthesized secretory and transmembrane proteins and actively 
participates in the quality control of these proteins. The term 'ER quality control' refers to 
the processes of conformation-dependent molecular sorting of secretory proteins (Hurtley 
& Helenius, 1989). By these means, actively folding proteins are retained in the ER and 
shielded from degradation pathways, folded proteins are destined for export and packaged 
into transport vesicles, and misfolded proteins are retained and ejected into the cytosol for 
ubiquitin-dependent degradation (Meusser et al., 2005; Ismail & Ng, 2006). 
Quality control in the ER is achieved by two independent mechanisms. The first 
one is the productive folding mechanism, which is involved in folding of ER-proteins and 
recognition ofmisfolding (Oda et al., 2006). The system must be able to distinguish between 
molecules that are actively folding, fully folded and misfolded (lsmail & Ng, 2006), a process 
that involves certain chaperones (Carvalho et al., 2006). Nevertheless, detailed information 
is lacking on how pro teins are initially selected for degradation (Denie et al., 2006). The 
second mechanism, comprising terminal steps of ER quality control, is termed ERAD, 
retrotranslocation or dislocation (Meusser et al., 2005). Recently, it has been suggested that 
autophagy could also play a role in protein quality control (Bemales et al., 2007). 
1.5.1. ERAD mechanism 
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The high flux of proteins into the ER together with the complicated multidomain 
nature of many secreted proteins, inevitably results in sorne fraction of proteins becoming 
tenninally misfolded (Denic et al., 2006). The ER must specifically identify tenninally 
misfolded proteins in an environment dominated by structurally similar folding intennediates. 
Proteins transiting the ER can be soluble or membrane bound with significant portions in 
the lumen, the membrane and the cytosol. To monitor misfolding despite this topological 
diversity and the misfolded substrate selection problem, the cell has developed distinct ERAD 
pathways. Substrates are targeted to an appropriate ERAD pathway depending on the site of 
the misfolded region. For instance, membrane and soluble proteins with luminal lesions are 
targeted to the ERAD-L pathway, whereas membrane proteins with misfolded cytoplasmic 
domains use the ERAD-C pathway (lsmail & Ng, 2006). Recently the ERAD-M pathway 
has been proposed for membrane proteins with misfolded intramembrane domains (Carvalho 
et al., 2006). These pathways diverge in their components, which are still not completely 
characterized. In general, the ERAD mechanism occurs in four steps: substrate recognition, 
translocation across the ER membrane, release in the cytosol and degradation (Figure 10). 
265 proteasome 
Rad23p1Dsk2p 
Degradation Dislocation and ubiqultlnation 
Figure 10. Proteasomal degradation of ERAD targets. Aberrant proteins are recognized 
within the ER lumen by the quality-control machinery and escorted to a putative channel 
that facilitates their export to the cytoplasm. Exposed lysine residues are ubiquitinated by 
ubiquitin ligases. Dislocation is completed with the help of the Cdc48p/p97 and membrane-
extracted substrates are conveyed to the proteasome by accessory factors such as Rad23p and 
Dsk2p. Adapted from (Meusser et al., 2005). 
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Importantly, misfolded proteins are not the only substrates for ERAD, which is also 
required for the regulated turnover of ER resident proteins. The regulated breakdown of a 
key enzyme of the mevalonate pathway, HMG CoA, is controlled by this system (Hampton, 
2002). Other examples include the o-opioid receptor and the MHC 1 (Shamu et al., 1999; 
Petaja-Repo et al., 2001). In addition, it is now clear that elements of the ERAD system 
are exploited by human pathogenic viruses. For example, two membrane-anchored proteins 
encoded by the human cytomegalovirus (HCMV), US2 and US Il, bind to MHC 1 molecules 
in the ER and initiate their dislocation into the cytoplasm where they are degraded by the 
proteasome (Wiertz et al., 1996). 
1.5.1.1 Substrate recognition 
Polypeptides that do not me et the quality control standards are retained within the ER 
and delivered to the ERAD ligases. In mammalian cells, the 1igase CHIP targets defective 
proteins whose cytoplasmic domains are recognized by the cytoplasmic chaperones of the 
HSP70-HSP90 family (Meacham et al., 2001). 
Polypeptides with native cytoplasmic domains are then examined for proper folding 
of the lumenal regions. The secretory pathway recognizes substructures within proteins 
such as hydrophobic patches, unpaired cysteines and immature glycans (Meusser et al., 
2005). Proteins trapped in the CNX/CRT cycle, which normally retain and assist the folding 
of immature proteins in the ER, are eventually trimmed by ER mannosidase 1 (Meusser 
et al., 2005). This leads to their recognition by EDEM, a lectin likely to be specific for 
Man8GlcNAc2-oligosaccharides. Presumably, EDEM then targets misfolded glycoproteins 
for degradation (Molinari et al., 2003; Oda et al., 2003). This mechanism allows the selective 
elimination of proteins that have failed to mature properly even after extensive folding 
attempts. Much less is known on how terminally misfolded proteins that lack N-glycans are 
targeted to destruction (Anelli & Sitia, 2008). 
Trimming of N-linked glycans is not the only mechansim that targets misfolded 
proteins for degradation. Aberrant proteins probable undergo partial unfolding and reduction 
before retrotranslocation (Anelli & Sitia, 2008). Both BiP/GRP78 and PDI have been 
implicated in this process (Molinari, 2002). BIP/GRP78 and other chaperones associate 
with hydrophobic surfaces of these proteins, whereas PDI and other oxidoreductases bind 
free thiols and control the formation of disulphide bonds between correct pairs of cysteine 
residues (Tsai et al., 2001; Wang & Chang, 2003; Schroder & Kaufman, 2005). 
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1.5. 1.2. Transport across the ER membrane 
Following recognition, misfolded pro teins are targeted to processing sites on the ER 
membrane for their extraction. Next, the substrate is transported across the ER membrane, 
a process that, at least for luminal proteins, probably requires a protein-conducting channel 
(Carvalho et al., 2006). The nature ofthis conduit is a particular debated issue. One plausible 
hypothesis is that retrotranslocation occurs through the Sec6l channel, the one used for the 
transport of proteins in the "forward" direction, from the cytosol into the ER (Meusser et al., 
2005). This has been supported by the fact that nascent polypeptides enter the ER in a largely 
unfolded conformation, and if export is mechanistically connected to the import machinery, 
then prote in dislocation should also require unfolding of substrates. In agreement with this 
idea, certain proteins are reduced and unfolded by PDI to prepare them for dislocation (Tsai 
et al., 2001). In contrast, however, sorne model ERAD substrates arrive in the cytoplasm in a 
folded state (Tirosh et al., 2003). N-linked glycans increase the size ofthe exported molecule 
ev en further, because sugar moieties are not removed until the glycoproteins arrive in the 
cytosol (Meusser et al., 2005). Thus, this implies either sorne structural flexibility of the pore 
or altemate translocation mechanisms. 
Other candidates for this channel have been proposed inc1uding the multispanning 
membrane prote in Derl-l in mammals (Derplis the homologue in yeasts) and the 
ubiquitin ligases Hrdl p and DoalOp (Gauss et al., 2006). Both ligases possess a number 
of transmembrane domains that could form a pore and could physically link dislocation to 
ubiquitination (Meusser et al., 2005). 
1.5. 1.3. Release in the cytosol and degradation 
When at least part of the substrate is exposed to the cytosol, E2 ubiquitin-conjugating 
enzymes and E3 ligases attach polyubiquitin tags to the protein, thus targeting it to destruction 
(Ismail & Ng, 2006). The substrates are recognized and fully extracted from the membrane 
by the p97 NCP-ATPase complex in mammals, or the Cdc48p ATPase complex in yeast. 
The extracted substrate is finally degraded by the 26S prote as orne in the cytosol 
(Romisch, 2005). In the case of glycosylated proteins, sugar moieties are previously 
removed by an N-glycanase to facilitate degradation by the proteasome (Anelli & Sitia, 
2008). Proteasome inhibitors generally impair dislocation, implying that the dislocation, 
ubiquitination and degradation steps are tightly coupled (Mancini et al., 2000). Moreover, the 
association ofproteasomes with the ER membranes (Kalies et al., 2005) may be important in 
coupling substrate extraction and degradation. 
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1.5.2. Autophagy 
It has been recently proposed that in addition to ERAD, cells can dispose of aberrant 
proteins by autophagy (Bemales et al., 2007). On one hand, inhibition of ERAD stimulates 
autophagy (Yorimitsu & Klionsky, 2007). On the other hand, blocking autophagy stimulates 
glycoprotein dislocation and degradation (Anelli & Sitia, 2008). 
1.6. ER stress and the Unfolded protein response 
The ER is highly sensitive to stresses that perturb cellular energy levels, the redox 
state or calcium concentration because these factors are necessary for optimum protein 
folding (Szegezdi et al., 2006). Consequently, multiple physiological or pathological 
conditions can affect protein folding: hypoxia, glucose starvation, underglycosylation 
of glycoproteins, calcium flux across the ER membrane, viral infection, elevated protein 
synthesis and secretion, failure ofprotein folding, transport or degradation (Ma & Hendershot, 
2004; Schroder & Kaufman, 2005; Zhao & Ackerman, 2006). These stress stimuli perturb 
the normal physiological state of the ER inducing ER stress (Schroder & Kaufman, 2005). 
Under conditions of ER stress, the quality control is inefficient and/or the client protein load 
is excessive compared with the reserve of ER chaperones (Marciniak & Ron, 2006; Oda et 
al., 2006). This imbalance results in accumulation ofunfolded proteins in the ER (Oda et al., 
2006). 
1.6.1. How cells cope with ER stress 
Unfolded proteins are prone to aggregation, which is toxic to the cell (Marciniak & 
Ron, 2006). Therefore, cells respond to ER stress by activating intracellular signal transduction 
pathways, collectively known as the UnfoldedProtein Response (UPR) (Schroder & Kaufman, 
2005). The UPR is in princip le a homeostatic mechanism developed to maintain the balance 
between the folding demand and the synthetic capacity of the ER (Schroder & Kaufman, 
2005; Marciniak & Ron, 2006). However, ifprotein misfolding is persistent and the normal 
ER functioning cannot be restored, signaling switches from pro-survival to pro-apoptotic 
(Rutkowski et al., 2006). Thus, the level of ER stress encountered by a cell dictates the nature 
of its UPR (Marciniak & Ron, 2006). 
The remedies that the cell uses to restore ER homeostasis are i) to decrease the folding 
demand and ii) to increase the folding capacity of the ER (Schroder & Kaufman, 2005). 
On one hand, the folding demand is decreased by attenuating translation, downregulating 
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transcription of genes encoding secretory proteins, selectively degrading rnRNAs encoding 
polypeptides destined for the ER lumen, and increasing degradation of slowly folding or 
misfolding proteins through ERAD (Schroder & Kaufman, 2005; Hollien & Weissman, 2006). 
On the other hand, the folding capacity of the ER is increased by i) promoting the synthesis 
of ER resident molecular chaperones and foldases involved in fol ding and ii) increasing the 
ER size to dilute the increased unfolded protein load (Schroder & Kaufman, 2005). 
1.6.2. The UPR acts through three main signal transduction pathways 
The UPR is mediated by at least three ER transmembrane sensors, PKR-related ER 
kinase (PERK), inositol-requiring enzyme-l (IRE 1) and activating transcription factor 6 
(ATF6) (Moenner et al., 2007) (Figure Il). In resting ceIls, aIl three ER stress receptors are 
maintained in an inactive state through their association with BiP/GRP78 (Szegezdi et al., 
2006). As explained above, BiP/GRP78 is an abundant chaperone within the ER that binds 
to folding proteins through interaction with exposed hydrophobic residues (Marciniak & 
Ron, 2006). Upon accumulation ofunfolded proteins, BiP/GRP78 dissociates from the three 
receptors, which leads to their activation and triggers the UPR (Schroder & Kaufman, 2005). 
PERK is thought to be the first arm of the UPR to be activated, followed by ATF6 and lastly 
IRE 1 (Szegezdi et al., 2006). The roles of these UPR mediators are explained below. 
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Figure 11. The UPR. Upon accwnulation ofmisfolded proteins, BIP/GRP78 dissociates from 
PERK, ATF6 and IRE], leading to activation of the three main signal transduction pathways, 
collectively referred as the UPR. Adapted from (Szegezdi et al., 2006). 
1.6.2. 1. PERK initia tes the translational arm of the UPR 
Dissociation of BiP/GRP78 from PERK initiates the translational ann of the 
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UPR, which constitutes a short-term adaptation to reduce the load of newly synthesized 
polypeptides entering the· ER lumen (Ron, 2006). This dissociation causes the dimerization 
and autophosphorylation of the serine threonine-kinase to generate active PERK (Szegezdi 
et al., 2006). Once activated, PERK phosphorylates eIF2a on SerS! (Moenner et al., 2007). 
The eIF2 complex is essential in all eukaryotes for new protein synthesis, since it recruits 
the initiator methionyl-tRNA to ribosomes about to begin translation (Asano & Hinnebusch, 
2001). Phosphorylation of eIF2a inhibits this activity and thus globally reduces cap-dependent 
prote in translation (Marciniak & Ron, 2006). Consequently, inhibition of protein translation 
aids cell survival by decreasing the load of nascent proteins arriving at the ER (Szegezdi et 
al.,2006). 
While the majority or RNA transcripts experience decreased translation during periods 
of increased eIF2a phosphorylation, a small and still poody defined subset is translated more 
efficiently, probably to fulfill basic cellular survival needs (Marciniak & Ron, 2006; Zhao & 
Ackerman, 2006). This paradoxical effect is due to the presence of multiple upstream non-
coding ORFs, that are still translated (Schroder & Kaufman, 2005). Genes carrying certain 
regulatory sequences in their 5' untranslated regions, such as IRES in the case ofBiP/GRP78, 
can bypass the eIF2a-dependent translational block (Femandez et al., 2002a). Another weIl 
characterized example is the transcription factor ATF4, which promotes cell survival by 
inducing genes involved in the amino acid metabolism, redox reactions, stress response, and 
prote in secretion (Harding et al., 2003) (Vattem & Wek, 2004). ATF4 induces the transcription 
factor CIEBP homologous protein (CHOP), also known as GADD153. During ER stress, aIl 
three arms of the UPR induce transcription of CHOP (Szegezdi et al., 2006). However, to 
upregulate CHOP prote in expression, the PERK- eIF2a-ATF4 branch is essential (Szegezdi 
et al., 2006). Thus, the effects of eIF2a phosphorylation are not restricted to attenuation of 
protein translation, but also include activation of a transcriptional program (Harding et al., 
2000). 
1.6.2.2. fRE1 activates the transcriptionaf arm o'the UPR 
The transcriptional arm of the UPR constitutes a long-term adaptation that increases 
the capacity ofthe organelle to handle unfolded proteins (Ron, 2006). This arm is induced in 
part by IRE 1. The IRE 1 dependent arm of the UPR is the most ancient in evolutionary terms 
(Tirasophon et al., 2000). IREI is a dual-activity kinase, possessing a serine-threonine kinase 
domain and an endoribonuclease domain. On activation, the endonuclease activity of IRE 1 
removes a 26-nucleotide intron from the X-box-binding prote in 1 (XBP 1) mRNA (previously 
induced by ATF6) (Szegezdi et al., 2006). The generated frameshift spliced variant (sXBPl) 
encodes a stable, active transcription factor (Yoshida et al., 2001). sXBPl has diverse 
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targets including ER chaperones and the HSP40 family member P58IPK (Lee et al., 2003). 
Upregulation of the latter is not an immediate event. P58IPK binds and inhibits PERK thereby 
providing a negative feedback loop that relieves the PERK-mediated translational block 
(Yan et al., 2002). AIso, both XBPI and ATF6 activate the transcription of genes involved in 
ERAD (Zhao & Ackerman, 2006). 
IRE 1 itself but not XBP 1 is also involved in posttranscriptional regulation of a 
specific mRNA subset (Hollien & Weissman, 2006). Probably, engagement of IRE 1 with 
nascent polypeptides encoding secreted and membrane proteins in the luminal side induces 
degradation of its encoding mRNAs (Ron, 2006). This IREI-dependent degradation of 
rnRNAs is likely to complement translational repression and further reduce the unfolded 
protein load on the stressed cells (Ron, 2006). 
1.6.2.3. Activation of the transcriptional arm of the UPR by ATF6 
The transcriptional arm of the UPR is also activated by ATF6. After dissociation of 
BiP/GRP78, ATF6 translocates to the Golgi apparatus where it is cleaved into its active form 
by two proteases, SP 1 and SP2 (Szegezdi et al., 2006). The released transcription factor moves 
to the nucleus and promo tes the transcription of genes with an ER stress response element 
(ERSE) (Schroder & Kaufman, 2005; Szegezdi et al., 2006). So far, the identified targets of 
ATF6 include ER chaperones such as GRP94, PDI, BiP/GRP78 and the transcription factors 
CHOP and XBPI (Szegezdi et al., 2006). Although ATF6 can induce CHOP transcription, 
no reports have linked ATF6 to ER-stress induced apoptosis. Hence, it seems that ATF6-
mediated signaIs are purely pro-survival and aim to counteract ER stress (Szegezdi et al., 
2006). 
1.6.2.4. Other effects of the UPR 
UPR also incurs profound indirect effects on other cellular processes. For instance, 
DNA microarray analyses suggest that ER stress upregulates the transcription of many 
secretory pathways components, including pro teins functioning in peptide translocation, 
glycosylation and folding in the ER, proteins involved in anterograde and retrograde transport 
between the ER and Golgi, and proteins implicated in secretion from trans Golgi (Travers 
et al., 2000). Without a functional UPR, protein translocation across the ER membrane is 
partially impaired (Ng et al., 2000). Moreover, proteins involved in lipid metabolism and 
heme biosynthesis are also upregulated by the UPR (Travers et al., 2000). This response 
also inhibits cell cycle at G 1 through inhibition of cyclin Dl translation via the PERK/eIF2a 
branch (Brewer et al., 1999). 
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Activation of ER stress signaling has been correlated with induction of cell death. 
Nonetheless, the mechanisms of ER-stress-induced cell death are still not fully understood 
(Rutkowski et al., 2006; Szegezdi et al., 2006). A strong link between ER stress signaling and 
apoptotic pathways has been established through the discovery of the physical interaction 
between the pro-apoptotic BCL-2 family proteins Bak IBax and the cytosolic domain of 
lREI (Hetz et al., 2006). Interestingly, this interaction is necessary for lREI activation (Hetz 
et al., 2006). IRE 1 can also activate the ASKIIJNK mitogen-activated protein kinase or p53 
pathways, resulting in commitment ofthe cell to apoptosis via the classic pathway (Rutkowski 
et al., 2006; Szegezdi et al., 2006). 
ER stress may also cause apoptosis through non-mitochondrial pathways. Capsase ·12 
is involved in this mechanism (Nakagawa et al., 2000). Cell death due to long-term ER stress 
may also induce oxidative stress. The gene encoding the oxidoreductase ERO 1 a is a target 
of the transcription factor CHOP (Marciniak et al., 2004). EROla participates in prote in 
disulfide bond formation during protein refolding to help relief ER stress, but in doing so also 
transfers electrons to molecular oxygen, forming reactive oxygen species (ROS). ROS are 
toxic to the cell and may lead to apoptosis (Zhao & Ackerman, 2006). 
1.6.3. The UPR in disease and normal physiology 
Besides serving to protect cells from normal variations that occur in the cellular 
environment, the UPR can also be activated in pathological conditions (Ma & Hendershot, 
2004). Numerous pathophysiological conditions are associated with ER stress, including 
viral infection, cancer, neurodegenerative diseases and diabetes (Zhao & Ackerman, 2006). 
Expression of mutant, folding-incompetent proteins is the basis for a wide variety of 
diseases termed ER storage or conformational diseases (Ma & Hendershot, 2004; Schroder 
& Kaufman, 2005). Accumulation of folding-incompetent proteins resistant to proteasomal 
degradation in the ER can completely disrupt the ER function and activate apoptotic-signaling 
pathways. This is the basis for many neurodegenerative disorders like Alzheimer's and 
Parkinson's diseases (Ma & Hendershot, 2004; Schroder & Kaufman, 2005). AIso, mutations 
in the cytosolic portion of membrane proteins can disturb folding of the ER-Iuminal part 
of the prote in and cause ER stress, as it is the case for a mutation in the cys tic fibrosis 
transmembrane conductance regulator (Schroder & Kaufman, 2005). 
Pancreatic failure associated with autoimmunity that occurs in type 1 diabetes, can 
result from misfolded mutant insulin that causes ER stress in pancreatic p-cells (Harding & 
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Ron, 2002). Mutations or over-activation of the PERK branch of the UPR can also lead to 
type l diabetes (Zhao & Ackerman, 2006). Furthermore, it has been shown that ER stress is a 
key player in obesity-induced type II diabetes. For instance, mice heterozygous for a targeted 
mutation of eIF2a (which can not be phosphorylated) become obese and develop diabetes on 
a high-fat diet (Zhao & Ackerman, 2006). 
ER stress and UPR have also been observed in tumors (Ma & Hendershot, 2004), but 
how UPR activation contributes to cancer celI survival is not clear. Many ER stress-related 
proteins such as BiP/GRP78 display an increased expression in cancers (Moenner et al., 
2007). In line with this, it has been found that hypoxia and glucose starvation, conditions 
often found in the core of tumors, can activate the UPR (Ma & Hendershot, 2004; Schroder 
& Kaufman, 2005). AdditionalIy, the PERK and IRE! branches of the UPR can upregulate 
the potent proangiogenic factor VEGF-A (Moenner et al., 2007). 
Viral infection can activate, but also modulate the UPR (Schroder & Kaufman, 2005). 
Sorne ex amples include the hepatitis Band C viruses, human HCMV, severe acute respiratory 
coronavirus, ilavivirus and the West Nile virus (Tardif et al., 2005; Chan et al., 2006; Yu et 
al., 2006; Li et al., 2007; Medigeshi et al., 2007). In general, viral infection leads to eIF2a 
phosphorylation, as part of an innate antiviral response antagonizing viral protein translation 
and triggering the UPR (Schroder & Kaufman, 2005; Marciniak & Ron, 2006). 
FinalIy, the UPR is essential to a range of normal physiological and developmental 
processes (Wu & Kaufman, 2006). These include the regulation of insulin secretion by 
pancreatic ~-islet celIs, the differentiation of immunoglobulin-secreting plasma celIs and 
osteoblasts, and the proliferation of hepatocytes (Wu & Kaufman, 2006). Moreover, UPR-
signaling pathways respond to the nutritional state of the celI and control regulatory gene 
clusters involved in metabolism and starvation responses (Schroder & Kaufman, 2005). 
These examples ilIustrate how the UPR signaling may ex tend beyond simply maintaining 
homeostasis of the ER (Schroder & Kaufman, 2005). 
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2. RESEARCH PROJECT 
2.1. Rationale 
Both the diversity and abundance of peptides presented by MHC 1 molecules at any 
given moment, determine the response of T lymphocytes and dictate eventual recognition 
and elimination of infected and neoplastic cells. This highlights the importance of studying 
conditions that affect the MHC I-antigen processing and presentation pathway that could 
potentially be applied in immunotherapy. Thereby, we were particularly interested in 
studying whether and how stress fui conditions that affect the homeostasis of the ER regulate 
presentation of peptides by MHC 1 molecules. 
2.2. Research question and hypothesis 
The UPR has pervasive effects on cell prote in economy: attenuation of general prote in 
synthesis, increased transcription of UPR-associated genes involved in prote in folding, and 
increased degradation of slowly-folding pro teins in the ER. Thus, the UPR alters prote in 
synthesis and degradation in order to reestablish cell homeostasis. However, these effects 
are mainly seen on proteins destined to the secretory pathway that need to be folded in the 
ER. Similarly, MHC I-peptide generation depends on prote in economy: MHC I-peptides 
are preferentially generated from rapidly degraded polypeptides relative to slowly degraded 
proteins. Since UPR depends on protein synthesis and degradation and these processes are 
crucial for peptide generation, we hypothesized that the UPR should have an impact on 
peptide presentation by MHC 1 molecules. Based on this hypothesis, we addressed two main 
questions in our work: 
1) Does the UPR affect MHC I-peptide presentation? 
2) Does the UPR differentially regulate expression of MHC I-peptides derived from a 
prote in destined to the ER versus a protein localized in the cytosol? 
2.3. Objectives 
2.3.1. General objective 
The main aim of this study was to determine whether and how the UPR affects 
presentation of peptides by MHC 1 molecules. 
41 
2.3.2. Specifie objectives 
Specifie objective 1: To assess the effect of the UPR on surface expression of MHC 1 
molecules in different celllines stressed with pharmacological agents. 
Specifie objective 2: To measure the effect ofthe UPR induced by glucose starvation or 
pharmacological agents, on presentation of the model peptide SIINFEKL by H2Kb molecules 
in EL4 cells. 
Specifie objective 3: To determine whether the UPR induced by glucose starvation or 
chemical ER stress, differentially regulates surface expression of ER- versus cytosol-derived 
SIINFEKL in EL4 cells. 
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3. METHODOLOGY 
As mentioned above, the main objective of our work was to study the effect of the 
UPR on MHC l -peptide presentation. For this aim, we used different experimental approaches 
that l will describe briefly in this section. More details can be found in the "Materials and 
Methods" section of the manuscript. 
3.1. Model for in vitro quantification of MHC I-peptide complexes 
It has been suggested that the subcellular localization ofa protein may influence MHC 
l presentation of peptides derived from that specifie prote in (Golovina et al., 2002; Leifert 
et al., 2004; Caron et al., 2005). Thus, we used molecular cloning, confocal microscopy and 
flow cytometry techniques to create a model to quantify MHC l presentation of peptides 
derived from a source prote in located in different subcellular compartments. 
3.1.1. DNA constructs 
Different variants of the hen egg lysozyme (HEL) were modified by polymerase 
chain reaction (PCR) (Armstrong et al., 1997; Qi et al., 2000). The constructs encoding HEL 
targeted to different cellular compartments (nucleus, mitochondria, cytosol, ER or secreted 
prote in) were fused to a minigene coding for the Ovalbumin-derived peptide SIINFEKL and 
the c-myc tag. PCR amplification products were subcloned into the pPCR -Script Amp vector 
and then cloned into the bicistronic plRES-EGFP2 vector. 
3.1.2. Localization of HEL protein variants 
COS-7Kb and HeLa-Kb cells were transiently transfected with these constructs. 
Transfected ce Ils were identified by expression of the EGPF protein. Proper localization of 
the HEL prote in variants was verified by confocal microscopy in transiently transfected cells. 
Antibodies against the c-myc tag, as well as organelle markers (CNX for the ER, mitoTracker 
for mitochondria and DAPI for the nucleus) were used to analyze the location of the HEL 
variants. 
3.1.3. Assessment of Kb·SIINFEKL surface expression 
The SIINFEKL peptide binds to the H2Kb MHC l molecule and cell surface Kb_ 
SIINFEKL complexes are specifically recognized by the 25-01.16 mAb (Porgador et al., 
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1997). We evaluated whether cells transfected with these constructs were able to process 
the peptide and thus express Kb-SIINFEKL at the cell surface. To this end, we transitory 
transfected HeLa-Kb cells with the constructs, labeled the cells with the 25-D 1.16 mAb and 
measured Kb-SIINFEKL abundance at the cell surface by fiow cytometry. 
3.2. Engineering of Kb-SIINFEKL stable transfectant cell lines 
The UPR is primarily orchestrated to decrease protein overload in the ER (Schroder 
& Kaufman, 2005). We therefore wished to determine whether the UPR would differentially 
affect MHC 1 presentation of peptides derived from a prote in source located in the ER 
(secretory pathway) versus the cytosol (non-secretory pathway). 
3.2.1. Stable transfectants 
EL4 thymoma cellline were used to generate stable transfectants because it expresses 
relatively high levels ofMHC 1 (Fortier et al., 2008). EL4 cells were stably transfected with 
the described plasmids encoding modified HEL targeted to the ER (HEL-ER-SIINFEKL) or 
to the cytosol (HEL-Cyto-SIINFEKL). Stable transfectants were selected by repeated cycles 
of fiuorescence-activated cell sorting (FACS) of EGFP-positive cells combined with drug 
resistance. Processing and presentation ofSIINFEKL in these stable transfectants was assessed 
by staining with the 25-D1.16 mAb. Two ofthese clones, denoted, EL4/HEL-ER-SIINFEKL 
and EL4/HEL-Cyto-SIINFEKL, which displayed similar amounts of Kb-SIINFEKL at the 
cell surface, were used in further experiments. 
3.3. Assessment of the effect of UPR on MHC I-peptide 
presentation 
To induce ER stress we used pharmacological agents and glucose starvation (Murray 
et al., 2004; Ozcan et al., 2008). UPR activation was monitored by upregulation of UPR 
markers by Western blot and quantitative real-time reverse transcriptase polymerase chain 
reaction (RT-qPCR) (Yoshida et al., 2001; Lee, 2005; Shang, 2005). MHC 1 and MHC 
I-peptide presentation were measured by fiow cytometry. MHC 1 transcript levels were 
analyzed by RT-qPCR. 
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3.3.1. Stress treatment 
Human (HEK 293 and HeLa) and mouse (EL4) cells were submitted to chemical ER 
stress. Cells were treated with different concentrations of dithiotheritol (DTT) or tunicamycin 
for various time periods. DTT rapidly disrupts disulfide bond formation in the ER, whereas 
tunicamycin prevents N-linked glycosylation. Glucose starvation was induced by culturing 
EL4 transfectant celllines in Dulbecco's modified Eagle's medium (DMEM) lacking glucose 
and sodium piruvate for various time periods. 
3.3.2. UPR induction 
Activation of the UPR was monitored by RT-qPCR analysis of the UPR markers BiPI 
GRP78, XBP-l and CHOP. In sorne cases, upregulation of BiP/GRP78 protein leve1 was 
evaluated by Western blot. 
3.3.3. MHC 1 expression 
Surface expression ofHLAA/B/C, H2Kb and H2Db was measured by flow cytometry 
in human or mouse celllines submitted to ER stress. Also, MHC l and ~2-m transcript levels 
were determined by RT-qPCR in these cells. 
3.3.4. Measurement of existent and newly generated Kb·SIINFEKL complexes 
Cell surface Kb-SIINFEKL complexes were quantified with the 25-D 1.16 mAb in cells 
previously stressed with pharmacological agents or by glucose starvation. We also evaluated 
the impact of the UPR on generation of new Kb-SIINFEKL complexes. After chemical stress 
or glucose deprivation, cells were acid stripped to elute existent MHC I-peptide complexes at 
the cell surface (Sugawara et al., 1987; Storkus et al., 1993; Fortier et al., 2008). Generation 
of new complexes was measured thereafter by flow cytometry. 
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Abstract 
Background 
Viral infection and neoplastic transformation trigger endoplasmic reticulum (ER) 
stress. Thus, a large proportion of the cells that must be recognized by the immune system 
are stressed cells. Cells respond to ER stress of any origin by launching the unfolded prote in 
response (UPR). The UPRregulates the two key processes thatcontrol major histocompatibility 
complex class I (MHC I)-peptide presentation: protein translation and degradation. We 
therefore asked whether and how the UPR impinges on MHC I-peptide presentation. 
Results 
We evaluated the impact ofthe UPR on global MHC I expression and on presentation 
of the SIINFEKL peptide. EL4 cells stably transfected with vectors coding HEL-SIINFEKL 
prote in variants were stressed with pharmacological agents or exposed to glucose deprivation. 
UPR decreased surface expression of MHC I at the prote in but not the rnRNA level. 
Consequently, presentation of SIINFEKL by H2-Kb molecules was reduced in chemically or 
physiologically stressed cells. Notably, stressed cells preferentially presented MHC I-peptides 
derived from an ER-retained as opposed to a cytosol-Iocalized protein variant. Furthermore, 
generation ofnew H2Kb-SIINFEKL complexes after acid strip was less affected for ER- than 
for cytosol-derived SIINFEKL. 
Conclusion 
Our results show that ER stress impairs MHC I-peptide presentation, and that it 
differentially regulates expression of ER- vs. cytosol-derived peptides. This work indicates 
how ER stress, a typical feature of infected and malignant cells, can impinge on cues for 
adaptive immune recognition. 
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Background 
The ultimate role of the immune system in host defense is to eliminate infected and 
transfonned cells [1,2]. A fundamental feature of infected and neoplastic cells is that they 
are stressed cells [3-5]. In line with this, the innate immune system uses receptors su ch as 
NKG2D to recognize stressed cells [4,6, 7]. One key question, however, is whether cellular 
stress can influence recognition of transfonned or infected cells by the adaptive immune 
system [4, 8]. 
The single feature uniting different stress stimuli (heat shock, hypoxia, viral 
replication, abnonnal proteins, starvation or transfonnation) is that they all ultimately lead 
to accumulation of unfolded or misfolded proteins in the lumen of the ER [4, 5] . Infection 
and neoplastic transfonnation increase prote in translation and thereby the folding demand on 
the ER [9, 10]. This is particularly true for cells submitted to hypoxia, nutrient deprivation or 
low pH in poorly vascu1arized bulky tumors, metastases and sites of inflammation [11, 12]. 
Moreover, acquisition of numerous mutations during tumor progression leads to accumulation 
of abnonnal proteins with an increased propensity to misfolding that further increase the ER 
folding burden [3, 13]. 
The ER responds to the accumulation ofunfolded proteins by activating intracellular 
signal transduction pathways, collectively called the UPR [14, 15]. The UPR is a highly 
conserved adaptive response that allows survival to limited stress but leads to apoptosis in 
the presence of overwhelming stress [16, 17]. Mammalian UPR acts through three main 
transducers (PERK, ATF6 and IRE 1) that are activated by dissociation of the mas ter regulator 
BiP /GRP78 [5, 15]. Activation of PERK leads to phosphorylation of the translation initiation 
factor eIF2a and attenuation of cap-dependent translation [18]. The endonuc1ease activity 
of IRE 1 generates a frameshift splice variant of XBP 1 encoding an active transcription 
factor that activates genes involved in protein degradation and controls the transcription of 
chaperones [19-21]. Targets of the c1eaved active fonn of ATF6 inc1ude the chaperones BiP/ 
GRP78 and GRP94, and the transcription factors XBP-1 and CHOP [17, 19]. Activation of 
these UPR transducers has pervasive effects on cellular prote in economy: i) attenuation of 
prote in translation, ii) increased degradation of ER proteins by ER-associated degradation 
(ERAD), iii) transcriptional activation of genes involved in the folding machinery of the ER 
and iv) increased degradation ofER-localized mRNAs [14, 22]. 
Presentation ofMHC I-associated peptides to CD8 T cells is tightly linked to prote in 
economy. MHC 1 peptides are preferentially generated from newly synthesized but rapidly 
degraded polypeptides relative to slowly degraded proteins [23, 24]. Following proteasomal 
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degradation, peptides are translocated into the ER where they undergo N-terrninal trimming, 
loading onto MHC 1 molecules and export at the cell surface [25-29]. Since the UPR 
regulates the two key processes that shape MHC 1 peptide processing (prote in translation and 
degradation) we reasoned that ER stress should impinge on MHC 1 peptide presentation. We 
addressed this question and found that MHC 1 presentation was impaired during ER stress 
induced by pharrnacological agents or glucose starvation. Moreover, ER stress differentially 
affected presentation of peptides derived from a prote in localized in the ER vs. the cytosoL 
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Results 
UPR activation impairs MHC 1 surface expression 
To induce ER stress we first used dithiotheritol (DTT), a chemical agent known to 
rapidly disrupt disulfide bond formation in the ER [30, 31]. Human HeLa and HEK 293 
cens were treated with a low or high concentration of DTT for 8 and 16 hours. Activation 
of the UPR was monitored by quantitative real-time reverse transcriptase polymerase chain 
reaction (RT-qPCR) analysis of BiP and XBP-l transcripts, which are known to be induced 
during ER stress [19, 32]. As expected, BiP and XBP-l mRNA levels were upregulated in 
DTT-treated cens compared to untreated cells (Figure lA). Ofnote, upregulation ofBiP was 
more dramatic in HeLa ceIls, while that of XBP-l transcripts was more important in HEK 
293 cens. 
To evaluate the effect of the UPR on MHC 1 expression, we quantified surface 
expression of HLA A/BIC on DTT-treated ce Ils by flow cytometry. Cells in later apoptotic 
stages were excluded from the analysis by gating on propidium iodide-negative cells. MHC 
1 expression decreased in a DTT dose-dependent manner at the surface of HeLa and HEK 
293 cells (Figure lB). Stressed cells expressed between 60 and 90% of the amount ofMHC 
1 expressed by untreated cells. Since one of the UPR transcriptional mechanisms is the 
degradati on of mRN As encoding secreted or membrane pro teins [22], we investigated w hether 
the decreased MHC 1 surface expression was due to down-regulation of MHC transcripts. 
Using quantitative RT-qPCR, we found that MHC 1 mRNA levels were not reduced in DTT-
treated cells. In fact, the abundance ofMHC 1 transcripts tended to increase in stressed cells 
relative to control cells (Figure 1 C). These results show that induction of ER stress for 8 
to 16 hours significantly decreased MHC 1 surface expression through posttranscriptional 
mechanism( s). 
Engineering of K"·SIINFEKL stable transfectant celllines 
Evidence suggests that subcellular localization of a prote in (e.g., in the cytosol vs. 
the secretory pathway) may influence MHC 1 presentation of peptides derived from that 
specific prote in [33-35]. Moreover, the UPR is primarily orchestrated to decrease prote in 
overload in the ER [14, 15]. We therefore wished to determine wh ether the UPR would 
differentially affect MHC 1 presentation of peptides derived from a source prote in located in 
the cytosol versus the ER. To this end, we created stable EL4 transfectant ceIllines expressing 
a chimeric prote in located either in the ER or the cytoplasm (Figure 2A). We selected the 
EL4 thymoma cellline as a model because it expresses relatively high levels of MHC 1 [35] 
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which allows us to assess changes of MHC l abundance over a wider range. To create the 
chimeric constructs, a minigene coding for the SIINFEKL peptide was fused to previously 
described plasmids encoding hen egg lysozyme (HEL) targeted to the ER or the cytosol 
[36, 37]. The Ovalbumin-derived SIINFEKL peptide is presented by H2Kb and cell surface 
expression of H2Kb/SIINFEKL complexes was assessed by staining with the 25-Dl.16 
monoclonal antibody [38]. As shown in Figure 2B, EL4 stable transfectants, denoted EL4/ 
HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL, can process and present SIINFEKL 
derived form the ER-Iocalized or cytosolic chimeric proteins, respectively. These two clones, 
which display similar amounts of Kb-SIINFEKL at the cell surface, were used in further 
experiments. 
UPR decreases MHC 1 surface expression in EL4 stable transfectants 
In preliminary experiments, we found that concentrations of DTT used for UPR 
activation caused apoptosis of EL4 cells (data not shown). To circumvent this caveat, we 
treated EL4 cells with tunicamycin, another UPR-inducing agent that prevents N-linked 
glycosylation in the ER. Treatment of both EL4 transfectants with tunicamycin for 16 hours 
did not cause significant apoptosis but resulted in stimulation of the UPR as indicated by 
up-regulation of BiP, XBP-l and CHOP transcripts (Figure 3A). Activation of the UPR with 
tunicamycin reduced cell surface expression of H2Kb and H2Db by 60-70% in both cell 
lines (Figure 3B). Notably, tunicamycin had similar effects on the two transfectant celllines 
inasmuch as EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL ce Ils showed similar 
ceIl surface MHC l down-regulation. RT-qPCR experiments showed that mRNA expression 
levels ofH2Kh, H2Db and ~2 -microglobulin were not decreased by treatment with tunicamycin 
(Figure 3C). In fact, similar to what we found in HeLa or HEK 293 ce Ils treated with DTT 
(Figure 1 C), tunicamycin-treated EL4 transfectants had a tendency to express higher levels 
ofMHC l transcripts relative to non-treated cells (Figure 3C). These results show that UPR 
induction leads to posttranscriptional attenuation of cell surface MHC l expression in stably 
transfected mouse ceIllines as it did in human ceIllines. 
UPR differentially affects expression of ER- vs. cytosol-derived SIINFEKL 
In the next series of experiments, Kb-SIINFEKL surface expression was quantified in 
EL4 transfectants grown in the presence of tunicamycin for 16, 21 or 30 hours (Figure 4A). 
During this time frame, abundance of cell surface Kb-SIINFEKL decreased by more than 
70% in treated relative to untreated cells. Furthermore, we found that although Kb-SIINFEKL 
expression was reduced in both ceIllines, it remained higher at an time points in EL4/HEL-
ER-SIINFEKL cens than in EL4/HEL-Cyto-SIINFEKL cens. We wish to emphasize that 
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differences in abundance ofKb-SIINFEKL among the two EL4 transfectant celllines treated 
with tunicamycin (Figure 4A) cannot be ascribed to an overall discrepancy in expression of 
H2Kb at the cell surface, since expression of H2Kb was reduced in the same extent in both 
celllines (Figure 3B). Thus, we observed a specific reduction in abundance of Kb-SIINFEKL 
complexes in stressed ce Us when SIINFEKL derived from a cytosol-Iocalized as opposed to 
an ER -retained prote in. 
Cell surface Kb-SIINFEKL complexes have been shown to be very stable [39]. We 
therefore postulated that monitoring of Kb-SIINFEKL in the aforementioned experimental 
conditions might lead us to underestimate the impact of ER stress on exportation of "new" 
MHC 1 -peptide complexes at the celI surface. Thus, in the next series of experiments, we took 
advantage of the fact that cell surface MHC I-peptide complexes can be disrupted by mild 
acid elution at pH 3.3 [40-42]. EL4 stable transfectants were treated or not with tunicamycin, 
then existent Kb-SIINFEKL complexes were acid stripped and generation of new complexes 
was measured at different time points (Figure 4B). We reasoned that in this way we cou Id 
directly assess the effect of the UPR on the generation of new Kb-SIINFEKL complexes. In 
the absence of tunicamycin, celIs rapidly re-expressed Kb-SIINFEKL and initiallevels were 
reached 9 hours after acid stripping (Figure 4C). EL4/HEL-ER-SIINFEKL and EL4/HEL-
Cyto-SIINFEKL celllines showed similar kinetics. In contrast, generation of new complexes 
was considerably reduced in tunicamycin-treated cells, as less than 20% ofnormallevels were 
regained after 18 hours. Moreover, EL4/HEL-ER-SIINFEKL celIs generated significantly 
more cell surface Kb-SIINFEKL complexes than EL4/HEL-Cyto-SIINFEKL (Figure 4C). We 
conclude that the UPR decreases presentation of existent and newly generated Kb-SIINFEKL 
complexes and that it differentially affects abundance of SIINFEKL derived from an ER- vs. 
cytosol-localized protein. 
Decreased MHC 1 expression during glucose starvation 
Though pharmacological agents are widely used to activate the UPR [16, 22], we 
wished to evaluate the effect of a more physiological ER stress stimulus on MHC 1 peptide 
presentation. Glucose is a prototypical and strong inducer of ER stress [43]. We monitored 
UPR induction in EL4 transfectants grown in high glucose (4.5mg/ml), low glucose (1 mg/ 
ml) or no glucose-containing medium for different time durations (Figure 5A). BiP, XBP-l 
and CHOP transcripts were significantly induced in celI deprived of glucose for more than 18 
hours, indicating activation of the UPR under these conditions. However, none of these UPR 
markers were up-regulated in ceUs grown in low glucose-containing medium. 
To evaluate whether UPR induced by glucose deprivation affects MHC 1 surface 
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expression, cells were deprived of glucose for 18 hours and MHC 1 surface levels were 
measured by flow cytometry. Glucose-deprived EL4/HEL-ER-SIINFEKL and EL4/HEL-
Cyto-SIINFEKL cells expressed only 25% and 30% of normal H2Kb and H2Db levels, 
respectively (Figure 5B). However, RT-qPCR analyses indicated that H2Kb, H2Db and ~2-m 
transcript levels did not change in cells deprived of glucose (data not shown). We conclude 
that alike DTT and tunicamycin, glucose deprivation induced ER stress and reduced cell 
surface MHC 1 expression through posttranscriptional mechanism(s). 
Differentiai cell surface expression of ER- vs. cytosol-derived SIINFEKL during 
glucose starvation 
We then asked whether presentation of ER- vs. cytosol-derived SIINFEKL could be 
differentially regulated during physiological stress as observed in chemically stressed cells. 
EL4 transfectants were deprived or not of glucose for 18 to 24 hours and Kb-SIINFEKL 
abundance was measured by flow cytometry using the 25-D 1.16 mAb (Figure 6A). Levels 
of Kb-SIINFEKL were significantly reduced in glucose-deprived cells as compared to cells 
grown in high glucose-containing media. Whereas both celllines displayed similar amounts 
ofKb-SIINFEKL complexes under normal conditions (Figure 2B), EL4/HEL-ER-SIINFEKL 
cells presented significantly more complexes than EL4/HEL-Cyto-SIINFEKL cells during 
glucose starvation. Thus, diminution of SIINFEKL presentation by H2Kb was more drastic 
when the peptide derived from a protein localized in the cytosol than from an ER-retained 
protein. 
We extended these findings to generation of new complexes in glucose-deprived cells. 
EL4 transfectants were grown under high glucose conditions or deprived of glucose for 18 
hours, then acid stripped to remove existing complexes and re-incubated in the appropriate 
media. Abundance of Kb-SIINFEKL complexes was thereafter estimated at different time 
points (Figure 6). Cells grown in glucose-containing medium showed a rapid generation of 
new complexes that reached normallevels by 9 hours (Figure 6B). Again, both transfectant 
celllines displayed similar kinetics. By contrast, glucose-starved cells were not able to reach 
basal amount of Kb-SIINFEKL after acid strip. At the term of the culture period, glucose-
deprived EL4 cells expressing HEL-ER-SIINFEKL had generated about 50% of cell surface 
Kb-SIINFEKL levels relative to cells grown in the presence of glucose. The proportion was 
significantly lower (30%) in glucose deprived EL4 cells expressing HEL-Cyto-SIINFEKL. 
Note that it was not possible to measure generation of complexes at time points later than 9 
hours after acid strip, since at this time cells were already glucose-starved for 24 hours and 
ceIl death became a confounding variable. The differential effect of ER stress on presentation 
of ER- or cytosol-derived SIINFEKL could be due to differences in the amount of source 
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protein. We explored this possibility and measured the level of HEL protein by Western blot 
in cells grown in high glucose-containing media or deprived of glucose for 18 to 24 hours 
(Figure 7). EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL expressed similar 
levels of HEL prote in both under normal conditions and during glucose starvation. This 
suggests that the different abundance of SIINFEKL at the surface of both clones during 
glucose starvation is not due to discrepancies in the amount of source protein. Together, these 
data indicate that physiological ER stress impairs MHC I-peptide presentation and that this 
inhibition is more striking for SIINFEKL derived from a cytosolic prote in than from an ER-
retained prote in (Figure 8). 
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Discussion 
The ER stands at the crossroad of two fundamental cellular processes: MHC 1 antigen 
presentation and UPR activation during ER stress. The UPR regulates protein synthesis and 
degradation, chaperoning and decay of ER mRNAs [14, 15]. Thus, it has enormous potential 
to impinge on MHC 1 antigen processing which relies on aIl these processes. Here, we 
assessed the effect of ER stress on the final outcome of antigen processing and presentation: 
MHC I-peptide abundance. We demonstrated that ER stress induced by pharmacological 
agents or glucose deprivation, decreases peptide presentation by MHC 1 molecules in human 
HeLa and HEK 293 cells and mouse EL4 thymoma ceIls. This finding is consistent with prior 
studies reporting reduced MHC 1 surface levels in hum an cells expressing a mutant HFE 
protein or overexpressing transcriptionally active isoforms of UPR activating ATF-6 and 
XBP-1 transcription factors [44, 45]. Thus, diminution of MHC 1 surface expression upon 
UPR activation appears to be a generalized phenomenon occurring during ER stress induced 
by a variety of stimuli (chemicals, mutant proteins, glucose starvation). 
Since the UPR provokes the degradation of ER-Iocalized mRNAs [22], accelerated 
decay ofMHC 1 mRNA might have been responsible for the reduction of cell surface MHC 1 
expression. However, the presence of normal or increased levels ofMHC 1 transcripts allowed 
us to exclude this possibility. A second possibility would be that reduced MHC I-peptide 
presentation reflects a direct effect of ER stress stimuli (DTT, tunicamycin, glucose starvation) 
on maturation ofMHC 1 molecules. However, de Almeida et al. showed that overexpressing 
UPR transducers (ATF-6 and XBP-l) in the absence of genuine stress stimulus resulted in 
decreased MHC 1 surface expression [45]. Thus, UPR by itself appears to be sufficient to 
diminish MHC 1 expression at the cell surface. Peptide delivery to the ER is the limiting 
factor in the assembly and presentation of MHC-peptide complexes [28, 46]. Our favorite 
hypothesis is therefore that decreased MHC 1 presentation is caused by restriction of peptide 
availability. During ER stress, transducers of the UPR seek to decrease the ER burden by 
suppressing translation initiation [14, 15]. Given that MHC 1 molecules preferentially sample 
polypeptides that are being actively translated [47], we posit that global attenuation of prote in 
synthesis during the UPR probably limits the amount of peptides available for insertion in 
MHC 1 molecules. 
A main conclusion of our work is that UPR-induced attenuation of MHC I-peptide 
presentation is more severe when the source protein is localized in the cytosol than in the ER. 
Our celllines expressing HEL-Cyto-SIINFEKL and HEL-ER-SIINFEKL displayed identical 
responses to tunicamycin treatment or glucose starvation. The two celllines showed similar 
up-regulation of UPR markers and equivalent reduction in cell surface levels of H2Kb and 
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H2Db. The sole difference concerned presentation ofKb-SIINFEKL complexes. This suggests 
that in stressed cells H2Kb molecules are loaded more effectively with SIINFEKL wh en the 
peptide originates from an ER- compared with a cytosol-derived protein. 
Only 1-2 out of every 10,000 peptides generated by the proteasome bind to MHC 1 
molecules[28].Ourdatathereforebegthequestion:howwouldanER-retainedproteingenerate 
more peptides than a cytosolic protein? We propose that this results from two discrepancies 
in the MHC processing of ER vs. cytosolic proteins. The first discrepancy involves ERAD. 
UPR transdueers specifieally enhanee degradation of proteins in the seeretory pathway in 
order to deerease ER folding load. Proteins destined to the secretory pathway are synthesized 
on ER-bound ribosomes and are cotranslationally translocated into the ER lumen [48]. 
During ER stress, eotranslational protein translocation is inhibited and newly-synthesized 
ER proteins are triaged for degradation [31, 49, 50]. Furthermore, retrotranslocation of ER-
resident proteins in the cytosol for proteasomal degradation is enhanced [51]. The second 
discrepancy concerns peptide binding to the transporter for antigen processing (TAP). Once 
in the cytoplasm, peptides derived from proteasomal degradation have a very short half-
Iife in vivo: around 7 s for 9-mer peptides [28]. More than 99% of peptides are degraded 
by cytosolic peptidases before they bind TAP (on the cytosolic side of the ER) and thereby 
enter the MHC 1 presentation pathway. Thus, the probability that a peptide generated by the 
proteasome will associate with an MHC 1 molecule should be maximal when the proteasome 
is loeated closest to TAP, that is, on the cytosolic face of the ER [52]. That is precisely where 
retrotransloeated ER proteins are degraded by the proteasome. In summary, we assume that 
during ER stress, MHC 1 peptide presentation is biased in favor of ER proteins because their 
proteasomal degradation is enhanced and the generated peptides emerge in the vicinity of 
TAP which facilitates their presentation by MHC 1 molecules. 
What might be the impact of the UPR on immune recognition of infected and neoplastic 
ceUs? ParadoxicaUy, if the decreased generation of MHC-peptide complexes results mainly 
from inhibition of translation, it could facilitate recognition of virus infected ceUs. UPR-
induced attenuation of translation is mediated by PERK-dependent phosphorylation of 
eIF2a. on SerS! [53]. Phosphorylation of eIF2a. hampers canonical cap-dependent translation 
initiation which regulates synthesis of 95-98% of cellular rnRNAs. However, viruses can 
use internaI ribosomal entry sites in their 5' noncoding region to initiate cap-independent 
translation [9, 54]. Thus, by preferentially repressing presentation of self peptides, the UPR 
could facilitate recognition of viral peptides (the needle in the haystack [55]). On the other 
hand, by repressing production ofMHC 1 -peptide complexes, the UPR may hinderpresentation 
of tumor antigens to CD8 T eeUs. Indeed, generation of optimal CD8 T cell responses is 
promoted by high epitope density on antigen presenting ce Us [56,57]. On the other hand, an 
58 
elegant study by Schwab et al. has shown that in presence of elF2a phosphorylation, cells 
can generate MHC I-associated peptides derived from cryptic translational reading frames 
[58]. In the future, we anticipate that high-throughput sequencing of the MHC 1 peptide 
repertoire [35] will allow us to further evaluate how ER stress molds the peptide repertoire, 
in terms of both peptide abundance and diversity. 
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Conclusions 
Our work shows that ER stress impinges on the MHC l peptide repertoire in two 
ways: by decreasing ove raIl IVIHC I-peptide presentation and by changing the relative 
contribution ER- vs. cytosol-proteins to the celI surface MHC l peptide repertoire. Since ER 
stress is a characteristic feature of infection and malignancy, dysregulation ofMHC I-peptide 
presentation could have major implications in the recognition of infected and transformed 
celIs by CD8 T lymphocytes. 
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Materials and Methods 
Cel/Unes 
HEK 293 and HeLa cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM) (OIBCO) supplemented with 10% fetal bovine serum (FBS) and antibiotics. EL4 
cells were grown in DMEM medium supplemented with 5% FBS and antibiotics. EL4 stable 
transfectants were grown in the same medium supplemented with 1000 )lg/ml of 0418. 
DNA constructs 
pHYKJHEL-ERlmyc and pCMV/HEL-Cyto/myc plasmids encoding ER-retained 
or cytoplasmic HEL, respectively, were provided by S. Ostrand-Rosenberg (University of 
Maryland, Baltimore, USA). The pHYRIHEL-ER plasmid contains the HEL gene fused to 
the ER-retenti on signal KDEL, whereas pCMV /HEL-Cyto codes for HEL with a modified 
N-terminus and lacks ER-retention signal. These plasmids have successfully been shown to 
target HEL to the ER or to the cytosol [36, 37, 59]. pHYKIHEL-ER and pCMV/HEL-Cyto 
were sequenced to ascertain correct sequence and reading frame. Fragments coding for HEL-
ER or HEL-Cyto were fused by PCR to the region coding for the Ovalbumin-derived peptide 
SIINFEKL, flanked by a sequence of 18 p.b. (LEQLESIINFEKLTEWTS, here referred as 
SIINFEKL) to assure peptide processing [60]. PCR amplification products were subcloned 
into the pPCR-Script Amp cloning vector (Stratagene, Cedar Creek, TX, USA). HEL-ER-
SIINFEKL or HEL-Cyto-SIINFEKL were excised and cloned into the bicistronic plRES-
EOFP2 vector (Clontech, Mountain View, CA, USA) to generate plRES-EOFP2/HEL-ER-
SIINFEKL and plRES-EOFP2/HEL-Cyto-SIINFEKL (Figure 2A). Both constructs were 
sequenced to ascertain correct sequence and reading frame. 
Stable transfectants 
EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL were generated by 
transfecting EL4 cells with the appropriate HEL-containing plRES-EOFP2 plasmid. 
Transfections were done with Lipofectamine LTX Reagent (Invitrogen, Burlington, ON, 
Canada) as instructed by the manufacturer. 24 hours after transfection, single cells expressing 
the brightest signal of EOFP were sorted by fluorescence-activated cell sorting (FACS) on a 
FACSAria cell sorter (BD Biosciences, Mississauga, ON, Canada). Stable transfected clones 
were further selected by drug resistance (1000 )lg/ml of 0418) in combination with repeated 
cycles ofFACS ofEOFP-positive cells. Clones expressing similar levels of Kb-SIINFEKL at 
the cells surface were selected for use in further experiments 
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Stress treatments 
Chemical ER stress was induced by incubating cells in fresh medium containing 2 
mM or 10 mM ofDTT for 8 or 16 hours, or 2.5J.1g/ml oftunicamycin for the indicated times. 
DTT and tunicamycin were purchased from Sigma-Aldrich (St. Louis, MO, USA). Glucose 
starvation was induced by culturing cells in glucose and sodium piruvate-free DMEM medium 
(GIBCO, Burlington, ON, Canada) supplemented with 5 % FBS and antibiotics for 18 hours. 
Control cells were grown in high glucose DMEM medium, containing 4500 mg/L of glucose 
and Il Omg/L sodium pyruvate supplemented with 5% FBS and antibiotics. 
Antibodies and flow cytometry 
MHC 1 molecules at the cell surface were stained with anti HLA A/BIC and APC-
conjugated anti-mouse IgG, (Clone X56), biotin-conjugated anti H2Kb (Clone AF6-88.5) and 
biotin-conjugated anti H2Db (Clone KH95), followed by streptavidin PeCy5. All antibodies 
were purchased from BD Biosciences. Kb-SIINFEKL levels were determined with the 
25-D1.16 antibody [38] followed by staining with APC-conjugated anti-mouse IgG] (Clone 
X56). J.W. Yewdell (National Institute of Allergy and Infectious Diseases, Bethesda, MD, 
USA) kindly provided the 25-D1.16 hybridoma. Propidium iodide (BD Biosciences) was 
used to exc1ude cells in later apoptotic stages from the analysis. Cells were analyzed on a BD 
LSR II flow cytometer using FACSDiva (BS Biosciences) and FCS Express software (De 
Novo Software, Los Angeles, CA, USA) [61,62]. 
Acid strip assay 
MHC I-peptide complexes were eluted with acid treatment as previously described 
[40-42]. Briefly, cells (~5 x 105) were resuspended in 0.2 ml of citrate phosphate buffer at 
pH 3.3 (0.131 M citric acidlO.066 M Na2HP04, NaCI 150mM) for 1 minute, neutralized 
with appropriate medium pH 7.4 and either reincubated in fresh medium or stained for flow 
cytometry. 
RNA extraction, reverse transcription and RT-qPCR 
Total RNA was isolated with TRIzol reagent (Invitrogen) according to the 
manufacturer's instructions. Purified RNA were reverse transcribed using the High Capacity 
cDNA reverse transcription Kit with random primers (Applied Biosystems, Foster City, 
CA, USA) as described by the manufacturer. A reference RNA (Stratagene, La Jolla, CA, 
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USA) was also transcribed in cDNA. Expression level of target genes was determined using 
primer and probe sets from Universal ProbeLibrary (https://www.roche-applied-science. 
comlsis/rtpcr/upl/index.jsp) or Applied Biosystems (ABI Gene Expression Assays, http:// 
www.appliedbiosystems.coml). Pre-developed TaqMan® assays for GAPDH and ~-actin 
were used as endogenous controls. RT-qPCR analyses were performed as described using a 
PRISM® 7900HT Sequence Detection System (Applied Biosystems) [63, 64]. The relative 
quantification oftarget genes was determined by using the l:::.l:::.CT (threshold cycle) method. 
Relative expression (RQ) was calculated using the Sequence Detection System (SDS) 2.2.2 
software (Applied Biosystems) and the formula RQ 2_L:\L:\CT. 
Statistical analysis 
The means of normally distributed data were compared using the Student t test, with 
a P value of < 0.05 considered significant. Data are presented as mean ± SD. Whenever the 
results are expressed as a percentage of control, the statistical analysis was performed on the 
actual value. 
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Figure 1. UPR impairs MHe 1 surface expression but not mRNA leveJ. HEK293 or Hela ce Ils were either 
non-treated or treated with 2 mM (blue bars) or 10 mM (red bars) OTT for 8 and 16 hours . (A) Activation of 
the UPR. Total RNA was extracted and BiP and XBP-l mRNA levels were analyzed by RT-qPCR. Expression 
levels were nonnalized to the endogenous control gene p-actin. Transcript levels oftreated cells were compared 
with basal mRNA values ofuntreated cells (dashed fine), which were set to 1. (B) UPR decreases MHC-I surface 
expression. Surface expression of HlA-A/B/C was detennined by flow cytometry. Representative histograms 
of one of three independent experiments show MFI values of untreated cells (black), cells treated with 2 mM 
(blue) or 10 mM (red) OTT for 8 (top) or 16 hours (bottom). Graphs on the bottom represent % ofMFI intensity 
in treated cells relative to untreated ce lis (dashed fine). (C) UPR does not decrease MHC-I mRNA level. HlA-A 
mRNA levels were assessed and analyzed as in A. Bars represent mean values ± SO from three independent 
experiments perfonned in triplicate. * P < 0.05; ** P < 0.01 when comparing OTT-treated with untreated cel\s. 
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Figure 2. EL4 stable transfectants express the SIINFEKL peptide derived from HEL targeted to the ER 
or to the cytosol. (A) Schematic representation of the constructs used to generate EL4 stable transfectants. 
Modified coding sequences of HEL [36, 37] in frame with the region coding for the Ovalbumin-derived peptide 
SIINFEKL and its flanking region were cloned lnto the pIRES-EGFP2 vector. HEL-ER-SIINFEKL possess 
the N-terminal signal peptide and the ER-retention signal KDEL and targets HEL to the ER; HEL-Cyto-
SIINFEKL contains a modified N-terminal sequence, lacks the KDEL ER-retention signal and targets HEL 
to the cytoplasm (See materials and methods). (B) EL4 stable transfectants express Kb-SIINFEKL at the cell 
surface. EL4 cells were transfected with the piRES-EGFP2 vector encoding HEL-ER-SIINFEKL or HEL-
Cyto-SIINFEKL. Stable transfectants were selected by repeated cycles of fluorescence-activated cell sorting 
ofEGFP-positive cells combined with drug resistance (1000 Jlg/ml ofG418). Cells were stained with 25D1.l6 
monoclonal antibody, recognizing the Kb-SIINFEKL complex, followed by staining with APC-conjugated 
anti-mouse IgG 1 as secondary antibody. Depicted in the graphs are EGFP and Kb-siINFEKL MFI values of 
the two representative clones that were used in further studies: EL4/HEL-ER-SlINFEKL and EL4/HEL-Cyto-
SllNFEKL. Percentages represent the proportion of cells expressing EGFP and Kb-SIINFEKL. 
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Figure 3. Induction of UPR decreases cell surface levels of H2Kb and H2Db in EL4 stable transfectants. 
(A) UPR activation in EL4 stable transfectants. EL4/HEL-ER-SIINFEKL cells were either non-treated or treated 
with 2.51lglml oftunicamycin for 16 hours. BiP, XBP-I and CHOP mRNA levels were analyzed by RT-qPCR. 
Expression levels were normalized to the endogenous control gene ~-actin. Expression levels of treated cells 
were compared with basal mRNA values of untreated cells (dashed fine), which were set to 1. Similar results 
were obtained for EL4/ HEL-Cyto-SIINFEKL (not shown). (B) UPR decreases surface expression of H2Kb and 
H2Db. Surface expression of H2Kb and H2Dh was determined by fiow cytometry in EL4/HEL-Cyto-SIINFEKL 
(bfue) and EL4/HEL-ER-SIINFEKL (green) cells. Representative histograms of one of three independent 
experiments showing MFI values of untreated cells (sofid fines) and tunicamycin-treated cells (dotted fines). 
Bars represent % of MF! intensity in treated cells relative to untreated cells (dashed fine). (C) UPR does not 
decrease MHC-I mRNA levels. H2Kb, H2Db and ~2-microglobulin (~2-m) mRNA levels were assessed and 
analyzed as in A. Bars represent mean values ± SD from three independent experiments performed in triplicate. 
* P < 0.05; ** P < 0.01 when comparing tunicamycin-treated with control cells. 
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Figure 4. Different peptide abundance in cells expressing ER- or cytosol-Iocalized HEL during ER 
stress. (A) Effect of UPR on pre-existing Kb-SIiNFEKL complexes. EL4/HEL-Cyto-SIINFEKL (bille) or 
EL4/HEL-ER-SllNFEKL (green) cells were either non-treated or treated with 2.5)lglml of tunicamycin for 
the indicated times. Abundance of Kh-SIINFEKL complexes was assessed at each time point by staining with 
250 l.J 6 monoclonal antibody and APC-conjugated anti-mouse IgG r antibody. Graph represents MFI values 
of tunicamycin-treated cells normalized to values of untreated cells, which were set to 1 (dashed fine) . (B) 
Study design to evaluate generation of Kb-SIINFEKL complexes. EL4 stable transfectants were non-treated 
or treated with tunicamycin for 16 hours . Existent Kb-SIINFEKL complexes were then stripped with acid and 
ce Ils were reincubated in fresh medium containing or lacking tunicamycin. Expression of new complexes was 
assessed thereafter as in A. (C) Effect of UPR on generation of new Kb-SIINFEKL complexes. EL4/ HEL-
Cyto-SIINFEKL (bille fines) and EL4/HEL-ER-SIlNFEKL (green fines) cells were incubated as explained in 
B. Kb-SIINFEKL expression was measured at the indicated times after acid strip. MFI values of unstripped 
cells grown under normal conditions and representing normallevel of Kb-SIINFEKL expression in each clone, 
were use to normalize MFI values of stripped cells . Bars represent me an values ± SO from three independent 
experiments performed in triplicate. "'P < 0.05; """P < 0.01. 
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Figure 5. Glucose starvation-induced ER stress impairs H2Kb and H2Db expression. EL4 stable 
transfectants were incubated in DMEM mediwn lacking glucose or containing low glucose Cl mg/ml) or high 
glucose (4.5 mg/ml) for different durations. (A) Activation of the UPR during glucose starvation. BiP, XBP-I 
and CHOP mRNA levels in EL4/HEL-ER-SIINFEKL cells were analyzed by RT-qPCR. Expression levels were 
normalized to the endogenous control gene ~-actin. Transcript levels of cells incubated under low (grey bars) or 
no glucose (black bars) were compared to levels of cells grown in high glucose medium (dashed fine), which 
were set to 1. Similar results were obtained with EL4/HEL-Cyto-SIINFEKL ce Ils (not shown). (B) Decreased 
cell surface expression of H2Kb and H2Db. EL4/HEL-Cyto-SlINFEKL (blue) and EL4/HEL-ER-SIfNFEKL 
(green) cells were deprived of glucose for 18 hours. Surface expression of H2Kb and H2Db was determined by 
flow cytometry. Representative histograms of one of three independent experiments showing MF! values of 
untreated cells (safid fines) and cells deprived of glucose (datted fines). Bars graph depicts % of MF! intensity 
of cells deprived of glucose relative to ce Ils grown in high glucose mediwn (dashed line). Bars represent mean 
values ± SD from three independent experiments performed in triplicate. * P < 0.05 when comparing low 
glucose or no glucose with high glucose conditions. 
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Figure 6. Increased presentation of SIINFEKL derived from ER-Iocalized relative to cytosolic proteins 
during glucose starvation. (A) Effect of UPR on pre-existing Kb-SIINFEKL complexes. EL4 stable 
transfectants were deprived of glucose or not for 18, 21 and 24 hOUTS. Kb-SIlNFEKL complexes abundance 
was assessed at each time point with the 25D1.16 monoclonal antibody and APC-conjugated anti-mouse !gG I 
antibody. Graph represents MF! values of glucose-deprived EL4/ HEL-Cyto-SIINFEKL (blue) or EL4/HEL-
ER-SIINFEKL (green) cells normalized to values of control cells, which were set to 1 (dashed line). (B) Effect 
of UPR on generation of new Kb-SIINFEKL complexes. EL4 transfectants were incubated in high glucose-
containing medium (top) or deprived of glucose (bottom) for 18 hours. Cells were submitted to acid strip to 
elute existent MHC-I complexes and expression of new Kb-SIINFEKL complexes was assessed as in A at the 
indicated times. MF! values of unstripped cells incubated under normal conditions and representing normal 
level of Kb-SIINFEKL in each clone were use to normalize MF! values of stripped cells. Bars represent mean 
values ± SD from three independent experiments performed in triplicate. * P < 0.01. 
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Figure 7. HEL expression during glucose starvation. EL4/HEL-ER-SIINFEKL or EL4/HEL-Cyto-
SlINFEKL cells were incubated in glucose-containing media or deprived of glucose for 18-24 hours. HEL from 
whole celllysates was detected by Western blot with anti-HEL antibody. p-actin was used as loading control. 
Representative gel ofthree independent experiments. 
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Figure 8. ER stress impinges on the MHC 1 peptide repertoire. ER stress decreases overall MHC I-peptide 
presentation and changes the relative contribution ER- vs. cytosol-proteins to the cell surface MHC 1 peptide 
repertoire. 
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5. SUPPLEMENTARY RESULTS 
5.1. Model for in vitro quantification of MHC I-peptide complexes 
5.1.1. DNA constructs and localization of HEL protein variants 
Besides the plasmids encoding HEL retained in the ER or destined to the cytosol, we 
engineered other plasmids encoding modified HEL targeted to other compartments: nucleus, 
mitochondria and secreted protein. (Figure SI). The protein variant targeted to the nucleus 
(HEL-nue) contains a nuclear localization signal (NLS) in triplicate derived from the simian 
virus 40 T antigen. The protein variant targeted to the mitochondria (HEL-mito) contains the 
mitochondrial targeting sequence of the cytochrome c oxidase. The third variant corresponds 
to secreted HEL (HEL-wt). These constructs also contain the region coding for SIINFEKL 
ftanked by five amino acids of the ovalbumin protein. They were inserted by PCR into a 
pIRES-EGFP2 vector. 
IRES H EGFP ~ 
Figure SI. Schematic representation of the HEL constructs and subcellular localization 
of the protein variants. COS-7Kb cell were transfecled with the conslrucls encoding 
HEL-SIIFENKL targeted to differenl cellular compartmens. Subcellular localization of the 
protein 24 boUTs after transfection. HEL (Hen egg lysozyme); c-myc: used as tag; IRES 
(internai ribosomal entry site) contained in the pIRES- EGFP2 vector; S: SIINFEKL; MTS 
(mitochondrial targeting sequence). 
In addition, we verified the proper localization of three of these protein variants 
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(mitochondrial, ER and secreted) by confocal microscopy (Figure SI). We transiently 
transfected COS-7Kb cells with the appropriate construct and 24 hours thereafter we identified 
transfected cells that expressed the EGFP protein. The cells were labeled with antibodies 
against c-myc (for HEL), calnexin (as ER marker) or MitoTracker (for mitochondria). DAPI 
staining was used for the nucleus. 
As shown in Figure SI, HEL-mito is correctly targeted to the mitochondria. Similarly, 
there is a perfect colocalization between HEL-ER and calnexin, confirming that this variant is 
retained in the ER. In the case ofHEL-wt, there is a good colocalization with the ER marker, 
confirming that this protein variant traverses the ER before being secreted. 
5.1.2. Presentation of SIINFEKL derived from HEL protein variants 
We then verified the correct processing and surface expression ofSIINFEKL in HeLa-
Kb and COS-7Kb cells transiently transfected with these plasmids (Figure S2). SIINFEKL, 
derived from HEL targeted to the nucleus, the mitochondria, the cytosol or the ER, or from 
secreted HEL was correctly processed and presented at the cell surface by H2Kb molecules 
in both cell lines (see blue gate, EGFP+ and Kb-SIINFEKL+). These results also show a 
clear correlation between the expression level of the EGFP prote in and the amount of peptide 
presented at the surface. To note, translation ofEGFP is cap-independent (IRES-dependent), 
whereas generation of SIINFEKL relies on the cap-dependent translation of HEL. These 
results suggest that cells with a high rate ofIRES-dependent translation do probably also have 
a high rate of cap-dependent translation and thus SIINFEKL presentation is high in these cells. 
This is based on the fact that MHC 1 molecules preferentially sample what is being actively 
translated, rather than what has been translated (Qian et al., 2006b). These results also show 
discrepancies in the amount of peptide presented depending on the localization of the source 
protein (see blue gate and %). However, these differences could be due to variations in the 
efficiency of transfection of each plasmid and not to different efficiencies in the processing 
of the peptide depending on the localization of the source protein. In summary, these results 
show that proteins localized in different subcellular compartments can be sources of peptides 
for presentation by MHC 1 molecules. 
78 
nucleus cytoplasm 
10= 10) 10 10' 10= 10) 10' 10' 
mitochondria ER 
..J 10' 
~ 
W 
10' IL 10' 
Z 
en 10) 10) 
• 
.c 
~ 
IL 
10= 10= 
~ 10= 10) 10 10= 10) 10' 10' 
secreted 
NFI EGFP 
Figure S2. Kb-SllNFEKL presentation in HeLa-Kb cells transfected with the constructs 
encoding HEL destined to different subcellular comparments. MF) (mean fluorescence 
intensity); yellow gate: untransfected cells; red gate: EGFP+/ Kb-SIINFEKL- cells; blue gate: 
EGFP+/Kb-SIINFEKL+ cells). One representative experiment out ofthree. Numbers indicate 
% ofcells. 
The plasmids encoding HEL-mito-SllNFEKL, HEL-nuc-SIINFEKL and HEL-sec-
SIINFEKL were not used to create stable EL4 transfectants to study the effect of the UPR 
on MHC 1 expression owing to time limitations. These plasmids represent valuable tools that 
could potentially be used to further corroborate our result showing that the UPR differentially 
regulates expression of peptides derived from a protein localized in the secretory (ER-
retained and secreted HEL variants) versus the non-secretory pathway (HEL located in the 
mitochondria, the nucleus or the cytoplasm). Furthermore, these plasmid could we used to 
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create other EL4 transfectants and answer other questions such as whether the intracellular 
localization of a protein could affect the peptide presentation at the cell surface. 
5.1.3. Expression of the BiP/GRP78 protein as marker of UPR activation 
Besides monitoring the induction of BiP/GRP78 transcript during ER stress, we also 
assessed the expression of the protein (Figure S3). EL4 cells were treated or not with DTT 
(0.5 and 1 mM) for 8 hours or with tunicamycin (0.5 and 2.5 Ilg/ml) for 16 hours. Then, the 
prote in content ofwhole celllysates was de termine d, subjected to sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred to PVDF membranes and 
immunoblotted with anti BiP/GRP78, anti calnexin and anti ~-actin mAbs, and horseradish 
peroxidase-coupled secondary antibody. The membranes were revealed using the advanced 
EeL chemiluminiscence system and analysed in a LAS300 imager. It is worth to note that 
treatment of EL4 cells with high doses of DTT (more than 1 mM) or for prolonged periods 
(more than 8 hours) caused a considerable rate ofapoptosis (not shown). 
BiP 
Calnexin 
p-actin 
DTT(mM) 
0.5 1 
TN (ug/ml) 
0.5 2.5 
-
Figure 83. Expression of BiP/GRP78 protein. EL4 cells were treated or not with DTT 
for 8 hours or with tunicamycin for 16 hours and the expression of BiP/GRP78 prote in was 
analyzed by Wester blot. TN: tunicamycin. 
These results show the upregulation of BiP/GRP78 protein in cells treated with 
low doses of DTT and tunicamycin but not with high doses. As expected, the level of the 
chaperone calnexin, which is not used as marker of the UPR, did not change. 1 will comment 
these results further in the Discussion. 
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6. DISCUSSION 
Our results show that ER stress impinges on the MHC l peptide repertoire in two ways: 
hy decreasing overall MHC I-peptide presentation and by changing the relative contribution 
of ER- vs. cytosol-proteins to the cell surface MHC l peptide repertoire. 
Given that the discussion of the results is included in the manuscript, in this section 
l will focus on results that were not exposed in the manuscript and deepen the discussion. It 
is important to note that the numbering of figures which l will refer to through this section 
corresponds to the figures in the manuscript, otherwise stated. 
6.1. Activation of the UPR in different ceillines 
In the first set of experiments, we used DTT or tunicamycîn to disrupt disulphide bond 
formation or N-glycosylation in the ER, respectively (Figures 1 and 3). We observed that the 
UPR induction profile, which was monitored by analyzing the transcript levels ofXBPl, BiPI 
GRP78 and CHOP, varied according to the ceIlline, the dose and type of chemical agent, as 
weIl as the duration of the treatment. 
First, these results suggest that different ceIllines exhibit different sensitivities to the 
same stress stimu1i. Differences cou Id be due to the fact that EL4 and HeLa but not HEK293 
are neoplastic cells. Of note, upregulation of XBPI was more important in HEK293 cells, 
white that of BiP/GRP78 transcript was more dramatic in EL4 and HeLa cells. Indeed, it 
has been found that increased expression of the chaperone BiP/GRP78 occurs in at least 
10 different cancers (Lee, 2005; Moenner et al., 2007). In line with this, microarray studies 
have shown that the rapidity of induction of certain genes by an active UPR differed between 
fibroblasts and HeLa cells submitted to the same treatment with DTT and this difference was 
attributed to intrinsic properties of the cells (Murray et al., 2004). 
Second, our results show that the nature of the UPR varied according to the dose of 
stressor used (Figure 1 and S3). Upregulation of XBPI transcript was similar or higher in 
HeLa and HEK293 cells treated with a high concentration of DTT (10 mM) than in cells 
treated with a low dose (2 mM), probably reflecting the dose-dependent extent of ER stress 
and UPR activation. However, this was not the case for BiP/GRP78 transcripts, a chaperone 
whose induction is widely used as a marker of ER stress. We observed that upregulation of 
BiP IGRP78 was greater in HeLa and HEK293 ce Ils treated with a low concentration of DTT 
(2 mM) than in cells treated with a high concentration of DIT (10 mM) and not the opposite 
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outcome (Figure 1). The same pattern was observed at the prote in level in EL4 cells treated 
with DTT (0.5 and 1 mM) and tunicamycin (0.5 and 2.5 )lg/ml) (Figure S3). The answer may 
lie in the ability ofBiP/GRP78 to block the apoptotic branch of the UPR through interference 
with caspase activation (Lee, 2005). Thus, the high induction of BiP/GRP78 mRNA (and 
its protein) observed in cells treated with a low dose of DTT may represent a major cellular 
protective mechanism for cells to survive, whereas the low induction observed with a strong 
dose of DTT could owe to activation of latter pro-apoptotic stages of the response. 
Third, we observed variations in the UPR pattern according to the type of stressor used 
and to the time oftreatment. Incubation ofEL4 cells in the presence ofvery low dose ofDTT 
(0.5 mM) for less than 8 hours was sufficient to activate the UPR as detected by an increased 
level ofBiP/GRP78 protein (Figure S3). On the contrary, longer treatments with tunicamycin 
(16 hours) or of glucose deprivation (18 hours) were required to reach an equivalent activation 
of the UPR. This is due to the fact that DTT causes immediate accumulation of misfolded 
proteins in the ER by reducing existing disulphide bonds, whereas tunicamycin and glucose 
starvation cause a more graduaI accumulation of misfolded proteins as old pro teins have to 
be replaced by newly synthesized proteins that have not been properly glycosylated (Murray 
et al., 2004; Lee, 2005). 
Thus, based on our experience, we recommended doing a cell line-specific dosage 
analysis of more than one UPR marker in studies involving the UPR. AIso, the use of more 
than one UPR inducer agent is highly recommended. 
6.2. Activation of 'the UPR during glucose starvation 
Though pharmacological agents are widely used to activate the UPR (HoIlien 
& Weissman, 2006; Rutkowski et al., 2006), we wished to evaluate the effect of a more 
. physiological ER stress stimulus on MHC I-peptide presentation. Thus, we chose glucose 
starvation on the basis that this stress occurs under a variety of circumstances in the living 
organism, including cancer (Ma & Hendershot, 2004). As expected, BiP/GRP78, XBPI and 
CHOP transcripts were significantly induced in cells deprived of glucose for 18 or 24 hours, 
indicating activation of the UPR (Figure 5A). This shows that a long-lasting period of glucose 
starvation is necessary to induce the UPR. Accordingly, previous studies done in chinese 
hamster ovary cells, have shown that 24 hours of glucose deprivation induces the cleavage 
of ATF6, which activates the transcription of BiP/GRP78 and CHOP (Nadanaka et al., 2006). 
It is very probable that effects of glucose starvation are delayed in comparison to those of 
chemical stressors. This could result in a graduaI decrease in the amount of oligosaccharide 
intermediates used for N-glycosylation and thus less glycosylation of newly-synthesized 
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proteins, leading to accumulation ofunfolded proteins in the ER and activation of the UPR. 
On the contrary, none of these UPR markers were upregulated in cells grown in 
low glucose-containing medium (1 mg/ml). This was surprising since this low amount of 
glucose, which is almost 4 times less that the amount used in normal culture medium (4.5 mg/ 
ml), was not sufficient to induce these UPR markers. However, cells grown in low glucose-
containing medium were indeed stressed because they showed increased apoptosis than cells 
grown under normal conditions. Furthermore, the amount of Kb-SIINFEKL at the surface 
of these cells was decreased in comparison with cells grown under normal conditions. This 
could mean that a reduced MHC I-peptide presentation observed in cells grown under low 
glucose conditions could be caused not by the UPR itself, but by other consequences of 
glucose starvation. For instance, glucose deprivation is known to affect the mammalian 
target of rapamycin (mTOR) pathway (Ozcan et al., 2008), which is the most prominent 
pathway responsible for regulation of translation (Tee & Blenis, 2005). On the other side, 
we can not discard the possibility that early events ofthe UPR that were not tested here, such 
as the translational repression through the PERKleIF2a branch, might have been already 
triggered in cells grown under low glucose conditions. Hence, we hypothesize that various 
effects of glucose starvation (attenuation of translation and/or mTOR dysregulation) could 
be responsible for a reduced expression ofIVIHC I-peptide complexes at the cell surface. In 
other words, we could state that the decreased abundance of peptides is a consequence of ER 
stress in general. 
6.3. Why UPR activation impairs MHC 1 surface expression? 
We demonstrated that ER stress induced by pharmacological agents or glucose 
deprivation, decreases MHC I surface expression in different cell lines: human HeLa and 
HEK293 cells and mouse EL4 thym orna cells (Figure 1). This finding is consistent with a 
recent study reporting reduced MHC I surface levels in 293T human cells or peripheral blood 
mononuc1ear cells, in which the UPR was induced by ER stress stimuli different from the 
ones used in our study (de Almeida et al., 2007). In those studies, carried out by de Almeida et 
al., expression of a mutant HFE protein, which causes hereditary hemochromatosis, induces 
UPR activation and impairs MHC I cell surface expression (de Almeida et al., 2007). They 
also found decreased surface MHC I expression in cells in which the UPR was activated by 
overexpressing the transcriptionally active isoform of ATF6 and XBPI (de Almeida et al., 
2005; de Almeida et al., 2007). Thus, altogether, our work and the work of de Almeida et al. 
suggest that diminution of MHC I surface expression upon UPR activation is a generalized 
phenomenon occurring during ER stress induced by a variety of stimuli (chemicals, mutant 
proteins, glucose starvation, and overexpression of UPR transducers). 
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Since the UPR provokes selective degradation of mRNAs encoding secreted and 
membrane proteins (Hollien & Weissman, 2006), accelerated decay ofMHC 1 mRNA (which 
encodes a membrane prote in) might have been responsible for the reduction of the MHC 1 
at the cell surface. However, the presence of basal or increased levels of MHC 1 transcripts 
allowed us to exclude this possibility. In addition, the fact that MHC 1 mRNA levels were not 
decreased despite the UPR-dependent degradation of ER-Iocalized rnRNAs, could suggest 
that the MHC 1 mRNAs contain a signal sequence that allows bypassing this degradation as 
is the case of BiP19RP78. Hoollien et al. have shown that the signal sequence determines 
whether an mRNA is targeted or not to the decay pathway during ER stress. For instance, 
the signal sequence of BiP/GRP78 allows escape from degradation and this is probably the 
case of other mRNAs encoding proteins that are important for the UPR or for vital cellular 
processes (Hollien & Weissman, 2006). In the case ofMHC 1 mRNA, it bypasses this selective 
degradation but not later unknown steps that lead to a decreased surface expression of the 
protein. 
We showed that induction of ER stress with pharmacological agents or by glucose 
starvation significantly decreased MHC 1 surface expression through posttranscriptional 
unknown mechanisms. One possibility would be that reduced MHC I-peptide presentation 
reflects a direct effect of ER stress stimuli (DTT, tunicamycin, glucose starvation) on 
maturation of MHC 1 molecules. MHC 1 is a prote in destined to the secretory pathway that 
requires N-linked glycosylation and disulphide bond formation for proper folding inside 
the ER (Zhang & Williams, 2006). Even though we did not assess the direct effect of the 
chemical agents or the lack of glucose on the maturation ofthe MHC 1 molecules, the results 
of de Almeida et al. argue against this hypothesis (de Almeida et al., 2007). They showed 
that overexpression of UPR transducers (ATF6 and XBP 1) in the absence of genuine stress 
stimulus resulted in decreased MHC 1 surface expression. Furthermore, despite this decrease 
at the surface level, the total amount of MHC 1 was not affected (detected in whole cell 
lysates). Thus, UPR by itself appears to be sufficient to diminish MHC 1 expression at the cell 
surface, without affecting its transcription or its translation, as demonstrated in our work and 
in the work of de Almeida et al., respectively. 
Peptide delivery to the ER is the limiting factor in the assembly and presentation 
of MHC I-peptide complexes (Neefjes et al., 1993; Yewdell et al., 2003). Our favorite 
hypothesis is therefore that decreased MHC 1 presentation is caused by restriction of peptide 
availability. During ER stress, transducers of the UPR seek to decrease the ER burden by 
suppressing translation initiation (Schroder & Kaufman, 2005; Ron & Walter, 2007). Given 
that MHC 1 molecules preferentially sample polypeptides that are being actively translated 
(Qian et al., 2006b), we posit that global attenuation of protein synthesis during the UPR 
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probably limits the amount of peptides available for insertion in MHC l molecules. In line 
with this, a probable dysregulation of the mTOR pathway during glucose starvation (Ozcan 
et al., 2008; Reiling & Sabatini, 2008) could also contribute to the repression of translation 
and thus restrict the amount of peptides available. 
Besides peptide restriction, malfunctioning of the peptide-Ioading complex (PLC) 
could also account to the decreased peptide presentation. Many chaperones involved in 
the folding of proteins in the ER such as PDI, CRT and ERp57 are also part of the PLC 
that assembles peptides onto MHC l molecules. Hence, we speculate that accumulation of 
misfolded proteins in the ER induced by DTT, tunicamycin or lack of glucose, probably 
keep these chaperones quite busy in retaining misfolding proteins to prevent aggregation. 
There will be presumably less chaperones available to form the PLC and to load peptides 
onto MHC l molecules and this could account to the decreased surface expression of MHC 
I-peptide complexes. 
AIso, it will be interesting to analyze the stability of MHC l -peptide complexes in 
stressed cells. It is very likely that not only the peptide supply is restricted and the peptide 
loading defective, but that the complexes that are produced have decreased stability at the 
cell surface. Other experiments seeking to determine the peptide-Ioading kinetics, the rate of 
endocytosis of MHC I-peptide complexes, as well as their retention time in the ER (which 
determines the extent of the peptide-Ioading optimization (Lewis & Elliott, 1998)) will be 
imperative to test this hypothesis. 
6.4. Why does UPR differentially affect expression of ER- versus 
cytosol-derived peptides? 
A main conclusion of our work is that UPR-induced attenuation of MHC I-peptide 
presentation is more severe when the source prote in is localized in the cytosol than in the 
ER (Figures 4c, 6b and 8). Our celllines expressing HEL-Cyto-SIINFEKL and HEL-ER-
SIINFEKL displayed identical responses to tunicamycin treatment or glucose starvation. 
Both cell lines showed similar upregulation of UPR markers and equivalent reduction in 
cell surface levels of H2Kb and H2Db. The sole difference concemed presentation of Kb_ 
SIINFEKL complexes. This suggests that in stressed cells H2Kb molecules are loaded more 
effectively with SIINFEKL when the peptide originates from an ER-destined prote in than 
from a protein localized in the cytosol. 
So, how wou Id an ER-retained prote in generate more peptides than a cytosolic 
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protein? We propose that this results from two discrepancies in the MHC processing of ER 
versus cytosolic proteins. The first discrepancy involves ERAD. UPR transducers specifically 
enhance degradation ofproteins in the secretory pathway in order to decrease ER folding load. 
As described in the introduction, proteins destined to the secretory pathway are synthesized 
on ER-bound ribosomes and are cotranslationally translocated into the ER lumen (Anelli & 
Sitia, 2008). During ER stress, cotranslationaf protein translocation is inhibited and newly-
synthesized ER proteins are triaged for degradation by the proteasome (Kang et al., 2006; 
Oyadomari et al., 2006). Furthermore, retrotranslocation ofER-residentproteins in the cytosol 
for proteasomal degradation is enhanced (Oda et al., 2006). In addition, non proteasomal 
degradation of ER proteins but not of cytosolic ones induced by ER stress (Shenkman et al., 
2007), could increase the contribution of ER- over cytosol-derived peptides to the peptide 
pool. It has been shown that this alternative nonproteasomal pathway involves a Mn2+/C02+-
dependent metalloprotease or other metalloprotein. 
The second discrepancy in the MHC processing of ER versus cytosolic proteins, 
concerns peptide binding to TAP. More than 99% of peptides are degraded by cytosolic 
peptidases before they bind TAP and thereby enter the MHC 1 presentation pathway. Thus, 
the probability that a peptide generated by the proteasome will associate with an MHC 1 
molecule should be maximal when the proteasome is located closest to TAP, that is, on the 
cytosolic face of the ER (Caron et aL, 2005). That is precisely where retrotranslocated ER 
proteins are degraded by the proteasome. ln accordance, work from our laboratory and other 
studies have shown that the location ofproteins in the ER in close proximity to ER-associated 
proteasomes can account for their contribution to the peptide repertoire (Leifert et al., 2004; 
Caron et al., 2005). 
Consequently, we decided to analyze the amount of HEL prote in in both cell lines 
during glucose starvation to have a rough estimate about their degradation (Figure 7). 
Nonetheless, we did not detect major differences in the net cytosolic or ER-retained HEL 
amount by Western blot of glucose-deprived EL4 transfectants. Nevertheless, more specific 
techniques to quantify protein translation and degradation rates should be more appropriate 
to test our degradation hypothesis. 
The enhanced degradation characterizing the UPR and that probably favors 
presentation ofER-derived over cytosol-derived peptides could also be promoted by defective 
folding and a consequent short half-life of the HEL-ER-SIINFEKL protein during ER stress. 
Nevertheless, this is not always the case. Sorne studies have shown that inducing misfolding 
of model proteins either through amino acid substitutions, substantial deletion or puromycin 
treatment (causes brief termination of prote in synthesis), had no impact on generation of two 
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epitopes. Only through the addition of a degradation signal (degron) was peptide production 
consistently enhanced (Golovina et al., 2005). Although we speculate that the folding of 
HEL-ER-SIINFEKL could be affected by tunicamycin treatment or glucose starvation, this 
will have to be confirmed. AIso, further experiments will be necessary to de termine whether 
the protein is degraded or not during ER stress. In summary, we hypothesize that during 
ER stress, MHC l peptide presentation is biased in favour of ER proteins because their 
proteasomal degradation is enhanced and the generated peptides emerge in the vicinity of 
TAP which facilitates their presentation by MHC l molecules. 
6.5. What might be the impact of the UPR on immune recognition of 
infection and malignancy? 
Paradoxically, if the decreased generation of MHC I-peptide complexes results 
mainly from inhibition oftranslation, it could facilitate recognition of virus infected cells. As 
described in the introduction, UPR-induced attenuation of translation is mediated by PERK-
dependent phosphorylation of eIF2a on Sersi (Shang et al., 2007). Phosphorylation of 
eIF2a hampers canonical cap-dependent translation initiation, which regulates synthesis of 
95-98% of cellular mRNAs. However, viruses can use internaI ribosomal entry sites in their 
5' noncoding region to initiate cap-independent (or lRES-dependent) translation (Holcik & 
Sonenberg, 2005; Tardif et al., 2005). Thus, by preferentially repressing presentation of self 
peptides, the UPR could facilitate recognition of viral peptides (the needle in the haystack 
(Yewdell, 2007)). Moreover, sorne cellular mRNAs also contain lRESs in their 5'-UTRs 
(Fernandez et al., 2002b). This is the case of BiP/GRP78, whose mRNA is translated under 
stress conditions via an IRES element found within its 5'-UTR (Fernandez et al., 2002b). 
Attenuation of cap-dependent translation during the UPR, could lead not only to presentation 
of viral peptides, but also ofpeptides derived from sorne cellular proteins such as BiP/GRP78 
and HSP70, whose translation is IRES-dependent under stress conditions (Baird et al., 2006). 
This could help explain why the expression of peptides derived from HSPs is enhanced under 
several cellular stresses, inc1uding viral infection (Hickman-Miller & Hildebrand, 2004). 
Because cancer cells are constantly exposed to ER stress stimuli such as glucose 
deprivation, hypoxia and low pH in the microenvironment of tumors (Moenner et al., 2007), 
our results could reflect the in vivo effect of ER stress on MHC I-peptide presentation, 
specially in bulky tumors. However, by repressing production ofMHC I-peptide complexes, 
the UPR may hinder presentation of tumor antigens to CD8+ T cells. Indeed, generation of 
optimal CD8+ T cell responses is promoted by high epitope density on antigen presenting 
cells (Wherry et al., 1999; Henrickson et al., 2008). On the other hand, an elegant study by 
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Schwab et al. has shown that in the presence of eIF2a phosphorylation, cells can generate 
MHC I-associated peptides derived from cryptic translational reading frames (Schwab et 
al., 2004). To note, cryptic peptides can elicit CD8+ T-cell responses iIi inice (Schwab et al., 
2003). On the other side, decreased MHC I-peptide abundance could also be recognized by 
inhibitory receptors, rendering stressed cells vulnerable to NK-cell (natural killer) mediated 
lysis (Yokoyama & Kim, 2006). Thus, although MHC I-peptide presentation is impaired 
during ER stress, modifications in the immunopeptidome colild be important in recognition 
of infection and malignancy through adaptive and innate mechanisms. 
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7. CONCLUSIONS AND FUTURE PROSPECTS 
The intracellular stress response has enormous potential to change the repertoire 
of peptides in the endogenous antigen presentation pathway. Many aspects of cellular 
metabolism on which antigen presentation depends, are affected under ER stress in cancer 
and infected cells. These inc1ude regulation of transcription and translation, degradation of 
proteins and chaperoning. Given all these common processes, we investigated whether and 
how ER stress affects MHC 1 presentation. Our results show that ER stress impinges on the 
MHC 1 peptide repertoire in two ways: by decreasing overall MHC I-peptide presentation 
and by changing the relative contribution ER- vs. cytosol-proteins to the cell surface MHC 
I-peptide repertoire. Since ER stress is a characteristic feature of infection and malignancy, 
dysregulation ofMHC I-peptide presentation could have major implications in the recognition 
of infected and transformed cells by CD8+ T lymphocytes. 
Based on our results obtained with the model peptide SIINFEKL, we expect that 
the composition of the whole immunopeptidome will change during stress. High-throughput 
studies aiming to sequence the MHC 1 peptide repertoire could allow us to further evaluate 
how ER stress molds the immunopeptidome, not only in terms of peptide abundance but 
also in terms of diversity. We anticipate that it will modify the repertoire of antigens that are 
presented and therefore reflect the level of intracellular stress and response mechanisms that 
the cell activates. For instance, proteins involved in the response to stress such as chaperones 
that are actively translated, as well as misfolded proteins, which are actively degraded 
by ERAD, could become major contributors to the MHC I-immunopeptidome. Peptides 
derived from cryptic translation could also become evident. We expect that by using mass 
spectrometry techniques, the repertoire of peptides presented by stressed cells, for instance 
malignant cells, could be characterized. Nevertheless, what might be the overall effect of 
the UPR on the immunopeptidome is not inherently obvious considering the many ways it 
affects cell protein economy. 
We are confident that the results of the CUITent work and future studies will provide us 
with unique insights relevant to two areas. First, to the understanding of cancer cell biology. 
Indeed, the set of peptides presented at the cell surface by MHC 1 molecules provides a 
unique perspective on what is being both translated and rapidly degraded in a cell. Second, 
our work is of prime relevance to cancer immunotherapy. It becomes imperative to de termine 
how ER stress, suffered by many cancer cells, molds the MHC 1 immunopeptidome and 
further discover peptides that could be used in cancer immunotherapy. 
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